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Abstract
Globalization in clinical research and development has increased since the 1990s.
Products approved in the United States (U.S.) and European Union (EU) include
increasing numbers of research participants from low- and middle-income countries. The
purposes of this quantitative correlational study were to investigate the lag time, or drug
lag, between U.S. approval and the approval of selected drugs in all countries that hosted
their pivotal clinical trials. The study population was limited to products approved first in
the U.S. between 2006 and 2015. The health capability model and research for health
justice framework were the theoretical frameworks for the study. Data were collected
from public reports and websites of the U.S. Food and Drug Administration (FDA),
European Medicines Agency, National Institutes of Health, local ministries of health,
National Association of Securities Dealers Automated Quotations, New York Stock
Exchange, the World Bank, and a subscription-based report from Springer Publications.
Data were analyzed descriptively, with inferential statistics performed via Wilcoxon and
chi-square tests. Independent variables were FDA approval year, drug indication, FDA
review type, orphan indication, host country World Bank income category, sponsor
market capitalization, and sponsor headquarters country. The dependent variable was
drug lag, in months. The U.S. to EU drug lag was significantly shorter than U.S. to last
host country drug lag. Lower host country income was also associated with longer drug
lag. Reducing drug lag may create justice for research participants, improve health
outcomes, and yield positive social changes.
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Section 1: Foundation of the Study and Literature Review
The number of clinical trials of new drugs has increased significantly since 1962,
the year the U.S. Food and Drug Administration (FDA) began requiring well-controlled
clinical trials to gain U.S. marketing approval (U.S. FDA, 2018b; Kinch, Haynesworth,
Kinch, & Hoyer, 2014). Furthermore, U.S. spending on prescription drugs has increased
more than 130-fold, from $2.5 billion in 1960 to nearly $330 billion in 2016, making the
United States the largest revenue market for prescription drugs in the world (Hartman,
Martin, Espinosa, Catlin, & The National Health Expenditure Accounts Team, 2018;
Liljenquist, Bai, & Anderson, 2018). The need for clinical trial data to support and
accelerate new product approvals in the United States, European Union (EU), and
Japanese markets has created a competitive environment for recruitment of human
subjects into clinical trials (Weigmann, 2015). To address this need for trial participants,
sponsor companies have shifted, since the 1990s, from domestically conducted trials to
global trials, increasingly including countries from the developing world (U.S. FDA,
2017a; Viergever & Li, 2015). Today, ex-United States participation is significant, as
93% and 72% of the pivotal trials supporting the FDA approvals granted in 2015 and
2016, respectively, included participants from outside the United States (U.S. FDA,
2017a, 2017c).
The first passage of the Prescription Drug User Fee Act (PDUFA) in 1992, has
transformed the FDA into a more predictable and transparent regulatory agency (U.S.
FDA, 2012). Clearer approval requirements and adherence to legally mandated timelines
for completion of new drug application (NDA) reviews has resulted from PDUFA (U.S.
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FDA, 2012). In the 25 years since PDUFA passage, the FDA has effectively eliminated
concerns in the United States over drug-lag, a term which refers to the discrepancy
between availability of approved drugs, particularly between the United States, EU and
Japan (Venkatakrishnan et al., 2016; Wardell, 1973; Wileman & Mishra, 2010; Yonemori
et al., 2011). PDUFA has since been refined and renewed five times, most recently in
2017, and its main guarantees are a decision on new drug approval within 6 or 10 months
depending on priority, establishment of an applicant user fee and investment of those fees
in technology upgrades, and hiring additional review personnel and development of more
efficient procedures across the agency, enabling more reviews to be completed annually
and ultimately granting access to a greater number of new approved drugs (U.S. FDA,
2012, 2017d).
Sponsoring company pursuit and prioritization of registration in the most
predictable and lucrative markets adheres to sound business principles and business
ethics, particularly for companies funded by the public capital markets (Hartman et al.,
2018; Poitras, 2009). Investigational drugs however, because they have possible salutary
but also unknown potentially harmful or fatal effects, warrant consideration by both
business and medical ethical standards (Emanuel, Wendler, & Grady, 2000; Poitras,
2009). Because new drug testing in the present globalized setting involves participation
of individuals in altered states of health in many different parts of the world, questions of
whether, when, and how companies seek drug approval in all participating countries is
important knowledge in determining whether equity and global social justice for research
participants and their communities are assured or if inequities exist. Quantifying any
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time-lag between FDA approval and drug approval in each country participating in
clinical trials is especially important in diseases where the treatment or curative window
is narrow or finite, such as with cancer (Prasad, Kumar, & Mailankody, 2016; Wileman
& Mishra, 2010; Yonemori et al., 2011). Should gaps in availability be found and/or a
consistent pattern of covariates contributing to “drug-lag” for developing countries be
identified, this may indicate possible exploitation of clinical trial participants from
different regions and an opportunity to reduce or eliminate that potential.
Fundamental medical ethical principles and public health ethics seek to create a
clinical research environment free of the social concern of patient exploitation (Council
for International Organizations of Medical Sciences [CIOMS], 2016; Freedman, 1987;
Freedman, Weijer, & Glass, 1996; Kass, 2004; National Bioethics Advisory Commission
[NBAC], 2001a). Twentieth century medical research provides several examples of
ethical transgressions following publication of court proceedings, ethical guidelines, and
best practices, sometimes by decades (Beecher, 1966; Emanuel et al., 2000). Therefore,
concerns and identified inequities related to the recent rapid globalization of clinical
research are valid, considering these historical delays in adopting best ethical practices.
Many ethical transgressions could potentially be addressed by a better definition of the
responsibilities of the physician-investigator and development of international regulations
better specifying the allocation of responsibilities to physician-investigators and research
sponsors (Banerjee, Hollis, & Pogge, 2010; CIOMS, 2016; Prasad et al., 2016; Pratt &
Loff, 2014; Schafer, 2010; Joint United Nations Program on HIV/AIDS [UNAIDS],
2012; World Medical Association [WMA], 2013). Just as the United States, EU and
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Japan have largely successfully eliminated drug-lag for their populations, the benefits of
PDUFA and cooperation between the United States, EU and Japanese regulatory agencies
should consider the access and well-being of all participants from all countries that
contribute trial data deemed pivotal for drug approval when making policy (NBAC,
2001b; Nuffield Council on Bioethics [NCOB], 2005; Prasad et al., 2016;
Venkatakrishnan et al., 2016; Wileman & Mishra, 2010). To date, a tabulation and
analysis of new drug approvals in all countries participating in pivotal clinical trials
relative to FDA approval has not been performed. The knowledge gained by this analysis
can assist in identifying specific countries or regions where local approvals lag behind
FDA approval. Further, measurement of the time length of approval lags and
identification of covariates associated with approval lag will be important to regulatory
agencies, researchers, and sponsors conducting trials in affected regions. This knowledge
can also assist in identifying which sponsoring companies prioritize expedient global
approvals, a factor that can be included in existing scorecards of corporate transparency
and ethical research practices in the pharmaceutical and biotechnology industries (Miller,
Wilenzick, Ritcey, Ross, & Mello, 2017).
In Section 1, I present the problem statement, the research questions and
hypotheses and a description of the theoretical foundations of the study. I also present the
literature review strategy and gaps in the current literature, discussion of the relevance of
this study, and present measures which can result in positive social change based on the
findings of this study. Section 1 of this study introduces the globalization trend in clinical
trial participation since the 1992 passage of Prescription Drug User Fee Act (PDUFA)
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and the practical and ethical implications of conducting human subject research across a
diversity of social, cultural, and economic geographies and demographics. I present a
multipart literature review, including a description of the role of the physicianinvestigator, a brief history of modern clinical research, foundations of medical ethics in
moral philosophy, contemporary research ethics and notable transgressions, a history of
the FDA, phases of drug development, and current FDA regulations and recent FDA
modernization. Historical articles and cases in medical ethics have also been included in
the literature review, as are the processes and time-frames for adoption of principles
codified in key ethical guidelines such as the Nuremberg Code, the Declaration of
Helsinki, CIOMS and the World Health Organization (WHO) guidelines, and the
Belmont Report (CIOMS, 2016; National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research, 2016; U.S. Department of Health &
Human Services, Office for Human Research Protections [OHRP], 2016; WHO, 2017;
WMA, 2013).
Problem Statement
Globalization of clinical research sponsored by United States , EU, and Japanese
companies has increased since the mid-1990s (Tufts Center for the Study of Drug
Development, 2009). Electronic and internet technology has facilitated globalization
across much of clinical medicine and medical research; and has increased the speed and
capacity of information transfer, thus lowering costs to institutions and companies
developing new therapies (Darrow, Sarpatwari, Avorn, & Kesselheim, 2015; Kesselheim
Avorn, & Sarpatwari, 2016). Figure 1 illustrates the decline in the United States, the
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plateau in the EU, and sextupling in rest of world (ROW) clinical investigators,
beginning approximately 20 years ago (Coleman & Bouësseau, 2008; Drain, Robine,
Holmes, & Bassett, 2014; Glickman et al., 2009; Tufts Center for the Study of Drug
Development, 2009). In addition to increases in ex-U.S., EU and Japanese investigators,
this globalization includes an increasing number of research participants from countries
outside the United States, EU, and Japan (U.S. FDA, 2017a; Tufts Center for the Study of
Drug Development, 2009).

Figure 1: Clinical investigators by geographic region 1997-2007. Adapted from: Tufts
Center for the Study of Drug Development, 2009.

Prioritizing approvals in the United States, EU, and Japan, the largest prescription
drug markets in the world, makes business sense considering that U.S. prescription drug
spending alone totaled nearly $330 billion in 2016 (Hartman et al., 2018). Analysis of
applications for approval of new medications between 2004 and 2013 demonstrated that
the majority of first in world approvals for new molecular entities (NMEs) are granted by
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the FDA (Bujar, McAuslane, & Liberti, 2014). This corporate preference for prioritizing
registration of drugs in the United States creates a potential injustice if foreign
participants in clinical trials do not receive the same priority and access to NMEs as
patients in the United States, EU, and Japan receive (Hartman et al., 2018). Several
international guidelines require prospective disclosures of posttrial access plans for
effective therapies, but debate exists on the definition of access, on a clear allocation of
responsibilities for providing it, and for what duration access should be provided
(CIOMS, 2016; Emanuel, Wendler, Killen, & Grady, 2004; Grady, 2005; Multi-Regional
Clinical Trials [MRCT], 2016; NBAC, 2001a; Sofaer et al., 2009; UNAIDS, 2012;
WMA, 2013).
The ethical concern over continued treatment for patients is relatively new in the
globalized clinical research context and has been inconsistently addressed on a short-term
basis by continuation of treatment in open-label extension studies or through programs
such as compassionate use (CIOMS, 2016; MRCT, 2016; NCOB, 2005; Pace et al., 2006;
WHO, 2017; WMA, 2013). However, in all but a few countries, sponsors are not required
to continue treatment indefinitely, nor are they required to seek approval in all countries
that provided research participants (Chieffi, Barradas, & Golbaum, 2017). Because
indefinite treatment is not appropriate for some diseases with narrow treatment windows,
such as cancer, other options have been proposed that create funds to subsidize
medications or invest in the healthcare infrastructure for communities that provided
research participants; however, sponsors and investigators are frequently unaware of the
need to prospectively plan, disclose, and form partnerships to ensure continued access in
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host countries (Ananworanich et al., 2004; Banerjee et al., 2010; Prasad et al., 2016).
This is further complicated by concerns of inconsistency in investigator qualifications,
improperly constituted ethics committees, corrupt practices, potential conflicts of interest
due to industry funding, and infrequent and delayed reporting of study results in peerreviewed journals for trials conducted in the developing world (Bristow et al., 2016;
Glickman et al., 2009; Miller, Korn, & Ross, 2015; Morreim, 2005; Vollebregt, 2010).
Therefore, trial participants from low and middle-income countries (LMICs) may be
especially vulnerable to lack of access altogether or to long lags in drug approvals
because of comparatively weak legal, medical, and ethical infrastructure, differences in
general and health literacy, differences in access to international standards of care, and
relationship dynamics with healthcare providers in their countries (Angell, 1997; Drain et
al., 2014; Emanuel et al., 2004; Lurie & Wolfe, 1997; Miller et al., 2015; Mitra, 2013;
van der Graaf & van Delden, 2012).
This increased reliance on data from participants in LMICs for FDA approval has
created new questions of research ethics surrounding provision of expedient access to
safe and effective treatments for all research participants (Angell, 1997; Emanuel et al.,
2000; WHO, 2017; Wileman & Mishra, 2010). Because all research participants take
risks when volunteering for clinical trials, if new drugs are not made equally available to
the entire populations that bore the risks to test these new drugs, the potential for
exploitation of human subjects is strengthened (Emanuel et al., 2004; Grady, 2005).
While there is not a one-size-fits-all solution to this problem of ensuring expedient access
to NMEs for all research participants regardless of the country in which they live, this
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analysis provides insight into whether a similar level of corporate prioritization for NME
approval-seeking occurs globally as it does in the United States. Analysis of covariates
also identify variables associated with delays in global availability and expedient access
to innovative treatments in all communities that bore the risks to test those medications
first approved in the United States (Pace et al., 2006).
Purpose of the Study
The primary purpose of this quantitative study was to examine, for the years
2006-2015, whether pharmaceutical and biotechnology companies that included foreign
patients in pivotal trials of NMEs sought approval in all countries providing research
participants in an expedient fashion relative to FDA approval. The independent variable
for the primary research question included all ex-U.S. countries contributing patients to
pivotal trials for FDA approval, and the dependent variable was elapsed time to approval
in all participating countries relative to FDA approval. The time to global approval was
transformed and coded into four categories of expediency: expedient, that is, within 1
year of FDA approval; average, that is, between 1 and 2 years; delayed, that is, between
2-5 years of FDA approval; or severely delayed, that is, greater than 5 years since FDA
approval. Research Question 2 considered the following seven covariates for impact on
global approval expediency relative to FDA approval: year of U.S. approval, drug
indication, orphan drug designation, FDA review type, host country income, and
headquarters location and market capitalization of the sponsor companies. Independent
variables were the seven covariates named above, and the dependent variable was time,
transformed into the four categories of expediency relative to FDA approval. For the
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years 2014 and 2015, the appropriate expediency category was applied based on the date
of statistical analysis of the drug-lag time, which was April 1, 2019.
Research Questions and Hypotheses
The primary research question was answered by secondary data sets containing
information on individual drug approvals from FDA, European Medicines Agency
(EMA) and Pharmaceuticals and Medical Devices Agency (PMDA), and the summary
basis of approval documents provided by FDA on their public websites. Research
Question 2 was designed to examine relationship(s) of covariates on the expediency of
drug approvals relative to approval by the FDA. For the primary research question
(RQ1), the context and time span of interest were those NME’s approved by the FDA
between the years 2006 and 2015. The dependent variable was elapsed time, coded into
one of four categories of expediency based on elapsed time from U.S. approval of each
drug to its approval in all countries that provided research participants in pivotal trials.
The time-period for each expediency category was defined by me: (a) approval in all
countries within 1 year of FDA approval was considered expedient, (b) approval in all
countries within 1-2 years was considered average, (c) greater than 2 but under 5 years
relative to FDA approval was considered delayed, and (d) approval in all countries in 5
years or greater relative to FDA approval was considered severely delayed. It was not
expected that all first NME approvals between 2006 and 2015 would include foreign
participants. The 66% threshold estimates for the null and alternative hypotheses for the
primary research question were based on the observed average frequency between 2004
and 2013 that the FDA’s approval was the first in the world (Bujar et al., 2014). I
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proposed that no greater than same proportion of drugs first approved by the FDA
between 2006 and 2015 would meet the expedient approval category, that is, approved in
all countries providing research subjects in pivotal trials within 1 year of the FDA’s
approval.
For Research Question 2, I examined each covariate for association with any
expediency category, expedient, average, delayed, or severely delayed in all countries,
relative to FDA approval for each drug between 2006 and 2015. The null hypothesis was
that covariates would not be associated with expediency categories (expedient, average,
delayed, or severely delayed). Bujar et al., 2014 reported the average approval times for
the FDA, EMA, and PMDA for the 2009-2013 period were 318, 480, and 363 days,
respectively, with the maximum difference in mean approval time observed between
2009 and 2013 as 162 days (480-318 days). Considering the 162-day difference, if
applications were filed to FDA and each participating regulatory agency within
approximately 200 days of each other, there would be a low probability of change in the
expediency outcome because categories span 1-year, 2-year, 2-5-year and greater than 5year periods. It was plausible that the premium market regulatory agencies would
improve their review times on an annual basis over the 2006-2015 period of the study;
however, it was unknown and beyond the scope of this study whether regulatory agencies
outside the United States, EU, and Japan would demonstrate similar improvements.
RQ1: Of the NME’s first approved by the FDA between 2006 and 2015 that
included foreign patients in pivotal trials, what proportion of sponsoring
companies achieved expedient approval in all participating countries?
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H01: Fewer than 66% of drugs were expediently approved (within 1 year of
FDA approval) in all host countries.
Ha1: Sixty-six percent or more of drugs were expediently approved (within 1
year of FDA approval) in all host countries.
RQ2: Are covariates of year of U.S. approval year, drug indication, FDA review
type, host country characteristics, and sponsor company characteristics associated
with specific approval time categories (expedient, average, delayed, or severely
delayed) in all host countries?
H02: Covariate types are not associated with specific approval time categories
in all host countries (expedient, average, delayed, severely delayed).
Ha2: Covariate types are associated with specific approval time categories in
all host countries (expedient, average, delayed, severely delayed).
Theoretical Foundation for the Study
The overall goal of my study was to examine relationships between variables
relating to the global availability of NMEs first approved in the United States between
2006 and 2015 that included foreign patient participation in trials deemed pivotal for the
product’s U.S. approval. This study includes only first approvals of NMEs in the United
States versus generics and supplemental approvals of NMEs previously approved in the
United States for different indications. I examined expediency of approval in all countries
contributing research subjects relative to U.S. approval as the primary outcome, and
thresholds of 1, 1-2 years, 2-5 years, and 5 years or greater were assigned categories of
expedient, delayed, and severely delayed, respectively. I also examined seven covariates
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thought to potentially influence expediency as a secondary research question; those
covariates were year of U.S. approval, drug indication, FDA review type, orphan
designation host country income, and the sponsor company headquarters location and
market capitalization. The theoretical framework selected for this study was Pratt and
Loff’s (2014) research for health justice (RHJ) framework, which was adapted from
Ruger’s (2010) health capability model (HCM). A description and understanding of the
HCM is valuable as a foundation for the later presentation of the RHJ framework (Pratt &
Loff, 2014). The RHJ framework describes the research environment for international
clinical trial subjects specifically, whereas the HCM framework describes an individual’s
perspective on a desire for health and their ability to pursue the necessary actions to
ensure good health (Pratt & Loff, 2014; Ruger, 2010). Both the HCM and the RHJ
models are also relevant to the concept of healthcare as a human right, a topic of
significant debate in the United States over the past 2 decades.
Health Capability Model Description, Philosophical Foundation and Relationship to
Research for Health Justice Framework
The HCM outlines factors in the environment that individuals and populations
seeking good health encounter on the personal and societal levels that affect their ability
to act as their own agents in pursuing good health (Ruger, 2010). There are two major
components of the HCM, and each is distinguished by (a) efforts of individuals to seek a
state of overall good health, and (b) recognition that the ability to successfully pursue a
state of good health is influenced by both internal and external factors (Ruger, 2010). The
HCM posits that the combination of the intrinsic desire to seek health and the ability to
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pursue good health can be aggregated into a composite termed health capability (Ruger,
2010). Health capability is composed of both barriers and advantages, and each is
influenced by both internal and external factors (Ruger, 2004, 2010). Self-directed factors
are generally expressions of autonomy, a fundamental ethical principle of selfdetermination, which in the research context is the foundation for informed consent. In
the health capability context, the principle of autonomy describes the individual’s ability
to make decisions about personal actions that are salutary, neutral, or harmful to health.
Conversely, health capability is also influenced by the principle of paternalism, defined
as involuntary prohibitions that assume that individuals are incapable or unlikely to make
choices that are healthy or those that lower risks (Ruger, 2010). Some examples of
paternalism are speed limits, laws prohibiting smoking in public, bans of trans-fat
containing foods, local taxes on beverages with high sugar content, and the schedule of
covered grocery items in Supplemental Nutritional Assistance Programs funded by
federal and state governments (Ruger, 2010; U.S. Department of Agriculture, 2017).
Frequently, paternalistic measures have a paradoxical effect when the health
consequences of a decision or of a physical state are not sufficiently rooted in the
prevailing societal logic, or when such measures are in direct conflict with social
constructions of autonomy (Resnik, 2010). In 2006, and 2008, respectively, New York
and California prohibited restaurants from adding trans fats to foods (Brownell &
Pomeranz, 2014). These state bans on trans fats are an example of an evidence-based
measure intended to reduce risks of cardiovascular disease at the population level
(Brownell & Pomeranz, 2014). However, the bans were controversial and initially
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unpopular because many trans fat containing foods were anchored to ethnic, cultural, or
religious identity (Resnik, 2010). The cardiovascular risk reductions of eliminating trans
fats were ignored, largely because at the societal level, making individual food choices is
regarded as a right with similar autonomous weight as freedom of speech or freedom of
religion (Resnik, 2010; Ruger, 2010). Ultimately, in an effort to reduce cardiovascular
risk at the U.S. population level, the FDA required content labeling, then removed trans
fats from the generally regarded as safe category in 2015, and has ultimately instituted a
federal ban of additive trans fats in all foods beginning in June of 2018 (U.S. FDA,
2018a). As healthier substitutes for partially hydrogenated oils were found that did not
alter the taste, convenience, or ability to prepare culturally valued foods, the prior
objection to paternalism waned, and today, trans fats are viewed socially as hazardous
(Brownell & Pomeranz, 2014; Resnik, 2010).
Similarly, when population-based methods to address the U.S. obesity epidemic, a
nonfatal condition, began to be discussed, there was resistance from additional
stakeholders, those without primary interests in health capability. In response to the City
of New York’s “portion cap” ban on sales of sugary drink serving sizes of greater than 16
ounces, the beverage industry responded by asserting that a greater proportion of the
causality for obesity was from inactivity versus from consumption of sugary beverages
(Herrick, 2009; Pomeranz & Brownell, 2014). Further, common associations of lean
body physical characteristics with health inspired a contradictory myth, notably promoted
by Coca-Cola, which was deemed the “obesity paradox” where it was reported that extra
weight, in both the overweight and obese body mass index ranges, conferred a protective
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effect on mortality for patients with heart attack, stroke, heart failure, and diabetes
(Banack & Kaufman, 2013). This counterintuitive claim for mortality was confusing, as
the establishment of obesity as a risk factor for development of cardiovascular disease
and type 2 diabetes was uncontroversial (Centers for Disease Control and Prevention
[CDC], 2017). The obesity paradox spawned dozens of additional cohort analyses and
statistical adjustments for selection bias among many experts. Ultimately, for patients
with heart failure, the originally quoted odds ratios for death for overweight and obese
persons were underestimated by 58% and 39%, respectively (Banack & Kaufman, 2013;
Lavie & Ventura, 2015). While the obesity paradox remains incompletely resolved, the
large portion sugary drink ban was found to be legally unconstitutional and was never
implemented in New York (Pomeranz & Brownell, 2014). These examples illustrate the
complexity of societal factors and influence of stakeholders in individual health
capability decision making, particularly when paternalistic forces such as regulations are
proposed (Ruger, 2010). In summary, for individuals, health capacity is influenced by a
significant number of factors that can alter decision making. Whether those factors
increase or decrease autonomy or modulate paternalistic measures, the individual’s
capacity for making the best health decisions is impacted. This could be in the context of
seeking treatment from a qualified physician, seeing information about a clinical trial, or
having the knowledge to ask about posttrial arrangements for continued treatment should
the investigational drug be safe and effective.
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Research for Health Justice Framework
The RHJ framework is specific to patient participation in clinical trials, and it is
anchored to Aristotle’s concept of the individual’s right to health and ability to flourish
(Papadimos, 2007; Pratt & Loff, 2014; Taylor, 1956). This flourishing includes a notion
that more affluent countries have a duty to reduce the disparities between the
communities that host their research, and the existing standards of care available to all in
the sponsoring nation (Pratt & Loff, 2014; Pratt, Zion, & Loff, 2012). The RHJ
framework is specifically built around 3 central tenets: 1) a focus on selecting appropriate
host countries for participation in clinical trials, 2) the commitment to strengthening
research capacity of the host community and 3) to contemplate and plan appropriately to
provide post-trial benefits (Pratt & Loff, 2014). Aristotle wrote that the soul is the seat of
the life force (Taylor, 1956). Additionally, it is the soul, through the body’s senses, that
enables consciousness to exist (Papadimos, 2007; Taylor, 1956). The human experience
of the world; pleasure, pain, thoughts, imagination, and desires are captured by the body,
and integrated and understood through consciousness, which is the force of the soul. The
integration of these experiences gained from an individual’s existence and their
interaction with other bodies, nature and souls, allows growth, and flourishing
(Papadimos, 2007; Taylor, 1956).
Aristotle believed that health was indispensable to both developing and
maintaining this flourishing and happiness, and it is this indispensability that the health of
the body must be a fundamental right to which each individual soul is entitled (Taylor,
1956). Aristotle also believed that there are influences on the soul and body at the
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community level, and communicating one’s desires and thoughts with other souls and
bodies is essential to flourishing (Taylor, 1956). Therefore, souls are not solitary forces,
rather, individual health is linked to the flourishing of one’s community (Dainesi &
Goldbaum, 2012; Taylor, 1956). Placing Aristotle’s concept of flourishing community
health into a contemporary and clinical research context; while individuals participate in
research, individuals have encounters with physician-investigators, and individual data
are collected, the community is impacted by the research, the observation, the
introduction of a new agent, and the effects, whether positive, negative, of the
observations themselves and the new drug being tested (Lavery et al., 2010).
State or national motivations for developing and maintaining a positive state of
health among its citizens are to create economic and technologic growth, invest in
education and infrastructure, decrease economic inequalities and health disparities, all of
which can impact domestic stability and security (Dyakova & Hamelmann, 2018). State
and federal governments can incentivize citizens to make salutary choices, and can
impose prohibitions or limit opportunities to make harmful ones (Ruger, 2010). In all
systems, healthcare and medical research lie at an intersection of physician’s duties to
patients, the prioritization the nation places on a healthy populace, the climate of
innovation in healthcare a government wishes to create, the incentives for research
sponsors, the amount of support the community and nation can offer to the sick, including
research participants, and the responsibilities of the physician-investigator to both the
research project and to the well-being of the participants under their care.
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International medical research sponsored by foreign companies creates additional
dimensions to the existing tension between the interests of the local patient, and the
interests of the sponsor. Sponsors have the business or academic interest of completing
the research quickly and with high fidelity, enabling rapid product approvals, often for
the benefit of patients in premium priced markets, to maximize shareholder return on
investment (Poitras, 2009). Developing countries, with weaker health and legal
infrastructure, are at increased risk when foreign sponsored clinical trials are hosted in
their communities. At its foundation, the RHJ framework contemplates this additional
tension created by sponsors’ business objectives and presents front-end mitigations to
minimize the probability that foreign sponsors of clinical research can conduct trials with
little community or national relevance, to benefit foreign versus host communities (Pratt
& Loff, 2014).
Within and between societies, justice is one of the fundamental ethical values that
must exist to establish an individual’s and a society’s sense of and belief in fairness.
Aristotle included a sense of fairness and justice in his description of a flourishing soul
and a flourishing society and Immanuel Kant included justice as one of the fundamentals
of his moral law (Taylor, 1956). Kant, in 1785, stated that no man can justify using
another man as a means to an end (Taylor, 1956). This fundamental statement in ethics
will be carefully examined in the foreign sponsorship of clinical trials in developing
countries context; a scenario where potential for departure from the fundamentals of
Kantian justice exists, both during and after completion of the foreign sponsored
international clinical research.
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Because the RHJ model was designed to address the specific context of
international medical research, its mission is to ensure justice across all populations
participating in clinical trials, while not impeding the advancement of medical science
and availability of new treatments to global patients (Pratt & Loff, 2014). The RHJ
framework includes assumption of obligations which commit medical research to
principles that inherently limit its capacity to exploit patients, beginning with elements
that ensure research is always prioritized to reduce the gap between the most vulnerable
patients and those most secure in their health (Pratt & Loff, 2014). RHJ is also grounded
in a fundamental principle that countries with higher incomes and levels of development
have obligations to LMICs to make the research locally relevant, and in the process
reducing health disparities in the host countries, a principle that is often not aligned with
shareholder value maximization (SVM) for corporations with publicly traded shares
(Poitras, 2009; Pratt et al., 2012).
RHJ framework also takes a community view, versus an individual view on
research participation, and considers the impact of the trial, the intervention and the
physician investigator on the community further into the future than simply the in-life
duration of the clinical trial (Pratt & Loff, 2014). RHJ provides proposals for long term
partnerships between academic, industry and non-profit organizations from higher
income research sponsor countries and the host countries. RHJ provides several
suggestions for allocation of expertise, assigning roles to the most experienced in areas
such as epidemiology, logistics, building infrastructure and research capacity building
over time with the goal of establishing or improving the permanent protective
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infrastructure through investments by entities which have performed research projects in
these communities (Pratt & Loff, 2014). Post-trial commitments are of particular interest,
as provision of continued access to drugs determined to be safe and effective for a fixed
period of time has been the most frequent exchange for performing research in the host
communities (Banerjee et al., 2010; Pace et al., 2006; Prasad et al., 2016; Pratt & Loff,
2014; WMA, 2013). As more experience has been gained, recognition that, if the first
condition of RHJ framework has been met e.g.; high local need for a treatment, providing
continued treatment for participants in the pivotal clinical trial does not consider incident
cases, nor the prevalent cases excluded from treatment in the research protocol.
Furthermore, expansion of the post-trial commitment tenet of the RHJ framework is
warranted, assuming data on prioritization of approvals from this study demonstrates the
potential for development or intensifying of a drug-lag between sponsoring and host
countries for international clinical trials conducted between 2006 and 2015 for which the
FDA was the first approving regulatory agency (Venkatakrishnan et al., 2016; Wardell,
1973; Wileman & Mishra, 2010; Yonemori et al., 2011).
In summary, the RHJ framework proposes several elements as priorities that do
not conform to the conventional business objectives of intellectual property protection,
revenue growth and SVM for the pharmaceutical and biotechnology companies
responsible for sponsoring the development of the majority of NMEs seeking approvals
by the FDA during the 2006-2015 period of this study (Poitras, 2009; Pratt & Loff,
2014). Additionally, many of the legal protections, particularly those of patents and
Intellectual Property (IP) in the United States, conflict with the RHJ objectives of

22
increasing access to new treatments and diminishing health disparities between the
developed and developing world (Pratt & Loff, 2014). Ironically, US patents and IP
protection impede global distribution of new products to patients in countries, including
those which contributed necessary data to the product approvals in the United States, EU
and Japan (Collier, 2013). Frequently, the matter of NME approval is discussed in a
business context vs a global health context, assigning responsibility for drug
disparities/drug-lag to developing countries whose legal systems are not empowered or
inclined to ensure patent and IP protection to a standard expected by US companies
(Collier, 2013). The net result in the worst case is an unfair exchange, especially in
countries contributing patients to NME development trials, of the risks of testing new
drugs, with reliable access to the drugs that are found to be safe and effective by
developed world regulatory agencies. If jurisdictions offering patent and IP protections
along with premium pricing are the primary drivers for corporate prioritization of
registration, then this study should demonstrate whether that pattern occurs during the
2006-2015 period. It is then a reasonable conclusion that significant time-lag in approvals
in developing world, or LMIC countries, is associated with corporate prioritization of
revenue from premium priced markets and SVM, versus reductions in health and
treatment disparities between developed and developing countries, a fundamental of the
RHJ framework (Pratt & Loff, 2014).
Nature of the Study
The nature of this quantitative methods study was to use publicly available
secondary data sources to determine the frequency and the time-lag in which new
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molecular entities first approved by FDA in the decade of 2006-2015 were made
available in all countries which hosted clinical trials deemed pivotal to FDA approval.
International guidelines from CIOMS, EMA, WMA and the RHJ framework state that
sponsoring companies have a duty to both close gaps in health disparities between host
and sponsoring countries, and to facilitate sustainable, post-trial access to successful
interventions in host communities (NBAC, 2001b; Pratt & Loff, 2014; WMA, 2013).
However, the frequency, durability and ubiquity with which post-trial access to
medications found to be safe and effective occurs in participating countries, particularly
those outside the US, EU and Japan was unknown (Pratt & Loff, 2014; UNAIDS, 2012;
WMA, 2013). The ensuing knowledge from these analyses of annual US drug approvals
and availability to all host countries provides clarification to the fundamental Kantian
question of whether some research participants have served as a means-to-an-end and if
so, for what duration (Papadimos, 2007; Walker, 1999). Meeting the threshold for the
means-to-an-end question is whether patient data benefits more fortunate patients in the
higher income countries of the United States, EU, and Japan before benefitting all
participants in all host countries for a period of 2 years or more (van der Graaf & van
Delden, 2012). Analysis of relationships between covariates and the time lag of treatment
availability provides insight on points for education and planning for sponsors, host
country governments, and regulators to prospectively minimize gaps in access and to
facilitate global availability of all NMEs, especially those which represent breakthroughs,
and treat diseases with high unmet needs. Determinants of time and approval gaps
relative to U.S. approval can potentially be addressed by regulators, sponsoring
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companies, international non-profit organizations, host countries, ethics committees,
professional societies or a combination of all will be clarified allowing resolution of any
identified disparities as suggested in the RHJ framework (Pratt & Loff, 2014).
This primary research question of this quantitative study examined, for the years
2006-2015, whether pharmaceutical and biotechnology companies that included foreign
patients in pivotal trials, sought local approval in all countries providing research
participants in an expedient fashion relative to U.S. FDA approval. The independent
variable for the primary research question included all ex-US countries contributing
patients to pivotal trials for FDA approval, and the dependent variable was elapsed time
to approval in all participating countries, relative to U.S. FDA approval. The time to
global approval was coded into 4 categories of expediency: Expedient, e.g.; within 1-year
of FDA approval, Average e.g.; between 1-2 years since FDA approval, Delayed, e.g.;
between 2-5 years since FDA approval, or Severely Delayed, e.g.; greater than 5 years
since FDA approval.
Table 1
Descriptions of Primary Outcome Variables
Expediency category
Expedient
Average
Delayed
Severely delayed

Definition
Approval in all participating countries within 1 year of FDA
approval
Approval in all participating countries between 1-2 years of FDA
approval
Approval in all participating countries between 2-5 years of FDA
approval
Approval in all participating countries in greater than 5-years
from FDA approval
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The second research question considered the following seven covariates for
impact on global approval expediency relative to U.S. FDA approval: Year of U.S.
approval, drug indication, FDA review type, Orphan designation, Host country income
and Sponsor company characteristics of market capitalization and headquarters location.
Independent variables were the seven named covariates, and the dependent variable is
time, which, as with the primary research question, was coded into the 4 categories of
expediency relative to US FDA approval. For the years 2014 and 2015, the appropriate
expediency category was applied as of the date of this analysis as of April 1, 2019.
Table 2
Expanded Descriptions of Covariates for Research Question 2
Covariate
Year of U.S. approval

Drug indication

FDA review type
Orphan designation
Host country characteristics
Sponsor company
characteristics

Description
Calendar year of FDA approval between 2006 and 2015
will be assessed for impact on expediency of drug
approval in all participating countries.
The specific approved indication, and indication type, e.g.
oncology, cardiovascular, anti-infective, rare disease will
be assessed for impact on expediency of drug approval in
all participating countries.
The FDA review classification; Standard Review (10
months), Priority Review (6 months).
Orphan designation (under 200,000 patients in United
States)
Host Country World Bank Income Category; Low,
Lower-Middle, Upper-Middle, High (World-Bank, 2017)
Country of Headquarters, Publicly Traded or Private,
Market Capitalization (if available)

The primary outcome data were collected from three secondary sources, two
within the US FDA and one from the Centre for Innovation in Regulatory Science
(CIRS); a neutral, independent, U.K. based subsidiary company of Thomson Reuters.
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Data from these 3 sources were aggregated into a master Microsoft Excel spreadsheet
organized serially by year and individual drug. Variables supporting the primary analysis,
e.g.; drug name, sponsor, date of FDA approval, countries involved in pivotal trials and
approval dates in each country were included, as were all details for covariates noted in
Table 1. The first FDA source was the annual NME approvals listing home page, hosted
on the FDA’s public website located at
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandA
pproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.h
tm. Annual approval reports for all drug and biologics NMEs approved between 1999 and
2018 are available on this public site. The reports include the drug name (generic and
trademark), the approved indication, approval date, sponsor name and the classification
of the review (priority or standard). The U.S. FDA is the regulatory agency,
headquartered in Silver Spring, Maryland, responsible for licensure of all new drugs,
biologics and medical devices in the United States. Their assessment of new drugs and
biologics requires that applicants demonstrate that their drug or biologic meets clinical
standards of efficacy, safety and standards of purity, through best practices in chemistry,
manufacturing and controls. The second FDA source (2014) is the public website housing
the detailed review information and conclusions arranged by section approval for each
individual approved drug. An example Drug Approval Package home page for the drug
FarxigaTM approved in 2014 is available here:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000TOC.cfm.
The section detail reports linked to each Drug Approval Package home page provide
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additional details on pivotal trials, their locations, review type and approval type. The
most relevant sections containing details for this study are the approval letter(s), the
summary review, medical review and statistical reviews. If necessary, additional details
for pivotal trials were obtained from a search of the National Institutes of Health (NIH)
clinical trials database (2019) www.clinicaltrials.gov, where additional trial specific
details are located (Zarin, Tse, Williams, Califf, & Ide, 2011).
CIRS reports on new drug approvals in the United States, EU, and Japan are
issued annually and list the approvals each year in the United States, EU, and Japan as
well as compare the previous 10 years of regulatory agency performance and present
trends analyses. CIRS data are collected from the FDA reports referenced previously, and
from similar reports provided by the EMA and the Japanese Regulatory Authority, the
PMDA. Links to examples of EMA and PMDA reports are included:
•

EMA:
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2018/01/W
C500242079.pdf

•

PMDA: https://www.pmda.go.jp/english/review-services/reviews/approvedinformation/drugs/0002.html

Data files from CIRS were requested, however they are not publicly available.
The authors of the CIRS R&D briefing reports did provide PDF versions of their reports
which covered the 10-year period of interest for this study. Relevant data were entered
from CIRS reports into the master excel spreadsheet for analysis by SPSSTM statistical
analysis software. Specific country drug approval dates outside the EU and Japan not
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available via internet searches e.g. via Google, individual sponsors were contacted by
email or telephone to determine the dates of approval in each country and those were
entered into the master excel spreadsheet.
Literature Review Literature Search Strategy
The literature search strategy was built upon several key areas of literature
necessary to cover the foundational topics providing context to this study of global
availability of new drugs approved between 2006 and 2015 in each country that hosted
trials deemed pivotal for the FDA’s approval. Those key areas are; Principles of current
and historical roots of ethics in human subject research, a brief history of human subject
research, the difference in obligations between the typical physician-patient relationship
and physician-investigator-to-patient relationship, FDA history, description of the FDA’s
drug development process and current regulations for drug approvals, and the concepts of
drug-lag and FDA review performance since the first PDUFA modernization act in 1992.
Several literature and agency databases were searched to obtain full articles and agency
reports in PDF format for review. The databases were selected based on greatest
relevance to medical and ethical journal articles and/or regulatory and economic report
content. The most cited journals include British Medial Journal and affiliated journals,
Journal of the American Medical Association and affiliated journals, Lancet, Nature, the
New England Journal of Medicine, American Journal of Bioethics, Bioethics and Journal
of Medical Ethics. The PubMed search engine for articles within the National Library of
Medicine and the Library of Congress databases were the primary tools for obtaining
peer reviewed journal articles and book citations. Google scholar was used as a search
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engine to access various government, regulatory and non-profit organization reports and
international guidelines, such as those from the World Bank, International Conference on
Harmonization (ICH), World Health Organization (WHO), the World Medical
Association (WMA), and the Council for International Organizations of Medical
Sciences (CIOMS) and the Organization for Economic Cooperation and Development
(OECD). Government organization and regulatory guidelines, reports, histories and
regulations are primarily from FDA, the U.S. Department of Health and Human Services
(DHHS), the EMA, and Japan’s PMDA.
Broad search terms included: globalization of clinical trials, clinical trials in
developing countries, philosophy of ethics, bioethics, history of medical ethics, post-trial
access, drug-lag, US and global prescription drug prices, pharmaceutical and
biotechnology revenue growth, FDA history, drug development process, and the PDUFA.
Journal articles, with the exceptions of those original publications providing
examples of historically important departures from contemporary medical ethics, range in
publication date from 1966-2018 and all were published in English. Selected reports
summarizing regulatory agency approval activities and history include data from 19902018. Textbook references range from 1958-2017. The literature review was organized
by the following broad topics; ethical principles and philosophy, ethics and the physicianpatient relationship in modern medical research, examples of departures from ethics in
lineal research, FDA regulatory history and policy in the 20th and 21st centuries, FDA
process of drug development and approval, globalization of clinical research, post-trial
access, revenue growth in prescription drug markets, and globalization of clinical
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research since the introduction of the PDUFA in 1992. Additional sections include
important bioethics cases in human subject research in the 20th and 21st centuries, and the
generation of contemporary ethical guidance through application of fundamental
principles in human ethics. Following a review of the roots of modern medical ethics in
moral philosophy, I briefly reviewed modern clinical research and some notable cases of
ethical transgressions. I also reviewed drug development and regulatory principles. I
summarize literature relating to my problem statement below, which includes primarily
regulatory agency reports and industry non-profit summaries which clarify the gaps in the
literature relating to medical history, medical ethics and the drug development process.
Human Subject Research: Physician Versus Physician Investigator
Human subject research, defined broadly, is any scientific investigation involving
the participation of human subjects that is intended to observe and evaluate the effects of
some variable on the human condition with the objectives of contributing to generalizable
knowledge on the disease, or an intervention’s impact on the patient and the disease
(Hellman & Hellman, 1991; Sheldon, 1999). Research on humans lies at the intersection
of medical practice and scientific investigation, and its pursuit of generalizable
knowledge creates a complex situation for the physician investigator when the clinical
encounter includes the addition of obligations to research (Freedman, 1987; Hellman &
Hellman, 1991). The physician-investigator must balance their primary responsibility for
the best interests of the patient, primum non nocere; first, do no harm, with the
requirements of the research protocol and the potentially broad applications of those
research findings to populations suffering from medical conditions (Emanuel et al., 2000;
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Freedman, 1987; Hellman & Hellman, 1991; Lázaro-Muñoz, 2014). Herein lies the
challenge of balancing the physician’s contract with the individual patient, and the
physician-investigator’s desire to conduct credible research, the results of which could
potentially impact populations positively (Lemmens & Miller, 2002; Lázaro-Muñoz,
2014; Morreim, 2005). Much legal and philosophical debate has occurred over whether a
legal framework can be applied to first, the physician-patient relationship, and second, to
the physician-investigator-patient relationship and how those two frameworks may differ
(Morreim, 2005). The physician-patient relationship is codified by many medical
societies, the majority of which have substantive grounding in both ancient and modern
principles of ethics. This context of this study is developed around the American Medical
Association’s (AMA) rubric for the physician-patient relationship as well as the
guidelines for conduct of physician-investigators, referenced in CIOMS, FDA,
International Council for Harmonization and WMA (AMA, 2016; WMA, 2013). The
physician and the patient form their relationship most often when the patient seeks the
consultation of the physician for diagnosis or treatment (AMA, 2016). At the foundation
of the physician’s code of ethics is a moral obligation for the physician to assist the
patient and address their suffering, even above the physician’s own self-interest (AMA,
2016; Papadimos, 2007). The partnership that the physician and patient form is based on
trust, and this trust binds the physician to use their best judgment to advocate for the
patient and their best health interests (AMA, 2016). Legally, this physician-patient
relationship has been described as fiduciary, with the physician being professionally
bound to act as an agent for the patient and their best interest, because the patient is both
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in weakened state of health, and because their medical knowledge and expertise about the
causes and treatment of their medical condition is less than their physician’s (Morreim,
2005). Therefore, from a legal perspective, there is general agreement that the physician
is the patient’s fiduciary agent based on the trust formed in the clinical encounter and the
moral obligation that the physician accepts when treating the patient (Lemmens & Miller,
2002; Lázaro-Muñoz, 2014). The physician-investigator relationship however has been a
topic that has been significantly debated within the legal and scientific communities,
particularly as clinical trials have globalized over the past 25 years (National Commission
for the Protection of Human Subjects of Biomedical and Behavioral Research, 2016;
Emanuel, 2013; Lemmens & Miller, 2002; Miller & Weijer, 2006; Morreim, 2005). As
the number of potentially therapeutic products under study, and the requirements of
regulatory agencies increased over the 20th century, the needs for physician-scientists has
expended significantly, however codification of physician-scientist responsibilities has
not occurred (Beecher, 1966; Schafer, 2010). This ambiguity has been at the foundation
of the discussion of ethical transgressions by physician-investigators throughout the
history of scientific inquiry into whether interventions intended to treat or curing human
diseases are safe and effective (Beecher, 1966). At its core is the question of whether the
physician-investigator trades off portions of their obligation to the patient as a physician,
in exchange for the scientific objectives of the overall clinical investigation (Lemmens &
Miller, 2002). To that end, significant debate among physician-investigators, physicians
and legal experts exists over whether the nature of the physician-investigator to patient
relationship is fiduciary in a similar way as the physician-patient relationship has been
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agreed to be (Lemmens & Miller, 2002; Miller & Weijer, 2006). Stated differently, there
continues to be debate over where the primary responsibilities of the physicianinvestigator lie. On one hand, the physician-investigator must be loyal to the best
interests and medical well-being of the patient as required by both their professional code
as physicians, and because the clinical protocol requirement medical stability. On the
other hand, the physician-investigator must ensure compliance with the clinical protocol
to ensure the generalizability of the research conditions and the data collected and
therefore this conceivably conflicts with the prioritization of a patient’s best interest
(Emanuel et al., 2004; Morreim, 2005; Orth & Schicktanz, 2017). Finally, in the context
of conducting clinical research in developing countries, questions exist over whether it is
the role of the physician-investigator to ensure that the sponsor of the research complies
with regulations and guidance regarding sustainable treatment, or the role of local
government to ensure that sponsors comply with international guidelines in the absence
of local laws (Emanuel et al., 2004; Orth & Schicktanz, 2017; Pace et al., 2006).
Brief History of Clinical Research in the Western World
References to scientific inquiry of factors influencing risk and benefits to human
wellness are recorded across societies through antiquity (Bothwell & Podolsky, 2016).
Beginning in the 18th century however, in parallel with the enlightenment, the scientific
literature began to contain discussions of methods and reports of observational and
interventional experiments in humans, such as those conducted in 1747 on the HMS
Salisbury by James Lind, which demonstrated the comparative efficacy of citrus fruits in
eliminating scurvy (Bothwell & Podolsky, 2016). Lind chose 12 sailors with scurvy and
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assigned 6 pairs to a range of treatments from a quart of cider daily, to a quart of sea
water daily, to daily consumption of lime or orange juice or a period of one week
(Bothwell & Podolsky, 2016). Within a week, Lind reported that the sailors assigned to
citrus consumption were so improved that they were assisting those assigned to the other
remedy groups (Bothwell & Podolsky, 2016).
More urgent than the prevention of scurvy in the 18th century however, was
action to protect the population from epidemics of smallpox surging throughout Europe
(CDC, 2016). Smallpox, now eradicated, was an infection with approximately a 50%
case-fatality rate that ultimately killed and disfigured hundreds of millions since at least
the time of ancient Egypt, (CDC, 2016; Riedel, 2005). Observations that smallpox
infection survivors became immune to infection during subsequent epidemics led to study
and acceptance of the practice of variolation (Riedel, 2005; Weiss & Esparza, 2015).
Variolation was introduction of material from the scabs or pustules of infected
individuals to uninfected persons, with the intention of inducing a mild infection in the
recipient, and thus preventing a full infection on future exposures to smallpox (Riedel,
2005).
Variolation had been practiced throughout Asia for centuries was introduced to
Britain after a diplomat’s wife observed the practice in Constantinople in 1717 and
advocated for its consideration during a 1721 epidemic (Riedel, 2005; Weiss & Esparza,
2015). Before widespread practice was permitted, two human experiments on the efficacy
of variolation were conducted in Britain in 1721; one in Newgate prison, where prisoners
were variolated and then re-exposed to live smallpox, and a second in St James Parish
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orphanage in London, where a similar experiment was conducted in children (Weiss &
Esparza, 2015). It is both unclear and unlikely that physicians explained all the risks of
variolation and sought and obtained informed consent of prisoners and children at this
time, however it is noted that the prisoners, all sentenced to death, were offered amnesty
if they survived (Weiss & Esparza, 2015). All the variolated prisoners and children
survived their subsequent exposures to live smallpox (Weiss & Esparza, 2015). Based on
the evidence provided from these experiments, the practice of variolation became
widespread in Britain, their colonies, and in many parts of Europe (CDC, 2016; Weiss &
Esparza, 2015).
In this context, in 1796, Edward Jenner summarized observational data, and
designed a demonstration that exposure to cowpox virus by dairy-maids conferred a
protective effect against contraction of smallpox infections (Riedel, 2005; Weiss &
Esparza, 2015). Jenner’s experiment was to “vaccinate” (latin root: vaca = cow) an eight
year old boy, Joseph Phipps, with material obtained from a cowpox pustule from a dairymaid’s hand (CDC, 2016; Riedel, 2005). Jenner then “vaccinated” others before
submitting his observations and experimental results to the Royal Academy in London
(Riedel, 2005). At the time, the enlightenment of scientific inquiry was well established,
however the connection between physician conduct and moral philosophy had not been
established. The 1721 Newgate prison variolation experiment demonstrates some
fundamental consideration regarding an exchange of a risk of smallpox infection and
death for a pardon, it is unclear whether consideration was given to the thought that the
prisoners were in a vulnerable position compared to the physician-investigators (Riedel,
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2005). The variolation experiment on children at St. James orphanage in that same year
demonstrates a likely conclusion that the experiment could be conducted more practically
in that group, and that orphaned children had some diminished social value compared to
children with living parents (Riedel, 2005). No exchange of risk-reward was noted in the
St. James orphanage experiment other than the possibility of conferring immunity to
future smallpox infections to the children.
The 19th and early 20th centuries brought significant further interest in generating
objective scientific evidence demonstrating an understanding of health and disease and
the efficacy of preventives and treatments to medicine. Generation of Pasteur’s germ
theory of disease followed the observational work of Semmelweis, Snow and Lister on
communicability of certain diseases (Best & Neuhauser, 2004; Gawande, 2004).
Commercial research, development, regulation and licensure of pharmaceutical and
biotechnology agents has experienced enormous growth in the past 120 years, and has
been a major contributor to the increases in global life expectancy observed in the 20th
century (Lichtenberg, 2017). Development of preventions and treatments for
communicable diseases such as smallpox, diphtheria, pertussis, tetanus, rabies,
tuberculosis, malaria, measles, polio, syphilis and other sexually transmitted diseases
were the primary objectives of pharmaceutical research and development for the first half
of the 20th century. The middle decades of the 20th century saw significant expansions of
both the number of clinical trials as well as the introduction of the first randomizedcontrolled trials (Kinch et al., 2014). The requirement for human studies demonstrating
safety and efficacy prior to drug approval contributed to the rapid expansion of products
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in commercial development in the 20th century (U.S. FDA, 2014b). After several tragic
incidents killed and disfigured many patients in the early-mid 1900s; from contaminated
serum, to contaminated sulfa elixir, to the teratogenic effects of thalidomide, regulation
of new drugs became progressively more stringent throughout the 20th century (Kinch et
al., 2014). From the 1960s to the present, with the exceptions of HIV and hepatitis,
clinical research has primarily focused on the development of treatments for noncommunicable diseases such as heart disease, cancer, diabetes and psychiatric disorders
(Kinch et al., 2014). U.S. licensure, production and administration of antitoxins and
vaccine began in the last decade of the 19th century has continued even into the 2000s
(Kinch et al., 2014). Sulfa and penicillin anti-infectives were developed in the 1930’s and
40’s, as were the first chemotherapies for the treatment of cancer (DeVita & Chu, 2008).
Biologics such as human insulin and growth hormone produced from recombinant DNA
technology began to be approved in the 1980s, and the first approvals of therapeutic
monoclonal antibodies began in the late 1980s (Kinch et al., 2014; Liu, 2014). Finally,
most recently, the first immunotherapies and cell therapies began to be approved in the
2000s, with now those giving way to the first approved human gene therapy in 2017
(Smalley, 2017). Therefore, while the 20th century has seen both monumental scientific
advances in therapies, it also witnessed some of the most severe ethical transgressions in
by physician-investigators that have occurred since human subject research began.
During World War II, and in the two decades thereafter some of the most well-known
ethical transgressions occurred, despite the development of the Nuremberg code
following the Nazi Doctors Trial in 1946-47 (Ferdowsian, 2011; OHRP, 2016). Several
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additional seminal documents providing ethical guidance have followed for sponsors of
human subject research and physician-investigators, including the Declaration of
Helsinki, the Belmont Report and the International Conference on Harmonization’s
Guidelines for Good Clinical Practice (National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research, 2016; International Council for
Harmonization, 2016; Wileman & Mishra, 2010; WMA, 2013). However, as the number,
study designs and scale of research projects have grown to their current global scale and
complexity, the ethics and the probability to inadvertently transgress has increased. Each
decade of the 20th and 21st centuries has provided often more than one example that the
ethical landscape changes in parallel with the growth of clinical research (Emanuel et al.,
2004). Contrasting forces remain the academic and commercial desire for generalizable
medical scientific information to gain approval and initiate sales, and the rights of each of
the human subjects who agrees to participate in a clinical trial, whether they believe, or
are told that the experiment is not designed to benefit them directly (Appelbaum,
Anatchkova, Albert, Dunn, & Lidz, 2012). Beecher, 1966, observed the growth of the
pharmaceutical industry in the first half of the 20th century and correctly anticipated that
the advances in scientific and medical technology would increasingly be funded by
industry. Therefore, a greater need for responsible practitioners of human subject
research would be required to decrease the risks of an unfavorable exchange between the
interests of the patient, and the interests of advancing medical science, the interests of
industry sponsors of research, and the interests of academic advancement for
investigators (Beecher, 1966). Beecher’s concern over the growth of the pharmaceutical
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and medical device industries and their impact on physicians and patients is similar to
President Dwight Eisenhower’s warning in his farewell address in January of 1961 of the
expanding influence of the military-industrial complex, and the distortions of power and
influence that accompany such expansion (Beecher, 1966; Eisenhower, 1961). The
timeline in figure 2 below illustrates with the parallel growth of human subject research,
some egregious examples of unethical research conduct by US investigators can occur
despite ethical guidance documents being developed for physician-investigators,
regulators and sponsors.
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Figure 2: Important historical moments in clinical trials and medical ethics.
Foundations of Medical Ethics in Philosophy
What philosophical grounding and mechanisms exist to ensure that appropriate
balance exist when priorities of the physician compete with the priorities of the
physician-investigator and the sponsor of the research? The physician-investigator’s
duties to patient and to research are bound by ethical principles contained in the moral
philosophies of universalism and utilitarianism, respectively. Universalism as a broad
principle begins with Aristotle in the 4th century B.C. and was elaborated by Immanuel
Kant in 1785. The general premise of universalism is that humans are composed of
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elements of both body and soul, with soul being the life-force, or what has come to be
known as consciousness, and the body and the senses being the interfaces with our
environment (Walker, 1999). That consciousness is the essence of humanity and the
within that essence is a right to flourish and be healthy, and that right to flourish forms a
portion of the essence of the duties of a physician to care for their patients (Papadimos,
2007; Taylor, 1956). In Kant’s 1785 Groundwork of the Metaphysics of Morals, he
outlines his construction of the moral duties of humans and how a sense of these duties
influences the actions one takes in an environment where man has free will (Kant, 2009).
Kant proposes that each man has inherent value, which it is every man’s duty to respect,
and that no man should take actions that use another man as the means to achievement of
a desired outcome/end (Kant, 2009).
Applying Aristotle’s and Kant’s principles to the sponsors of and physicianinvestigators participating in human subject research in the present context, the
appearance of a moral dilemma appears if all research subjects are not treated equally not
simply during, but after the completion of the clinical trial (Emanuel et al., 2004; Grady,
2005; Papadimos, 2007). Furthermore, both the research sponsor and the physicianinvestigator are faced with a tension between: a) upholding the duty to respect each
patient’s inherent value, b) the moral principle of not using another man as a means to
achieve a desired outcome, with c) ensuring the scientific integrity of the experiment, and
d) the advancement of science to improve and preserve human health at the population
level (Mandal, Ponnambath, & Parija, 2016; Schafer, 2010). As such, the physician
practitioner is not impacted by this tension, as his/her duty lies in assuring the best
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interests of the individual patient versus consideration of the integrity of a scientific
investigation and persons with whom he/she is not directly engaged in a physician-patient
relationship.
John Stuart Mill’s utilitarian philosophy serves a partial counter-weight to the
dilemma faced by the physician-scientist’s duty to preserve of the individual’s rights in
the context of a clinical trial. Utilitarian philosophy states that the approach which
provides the greatest amount of benefit for the greatest number of individuals, is the most
moral approach (Mill & Gray, 2008). Taking the utilitarian approach, the investigator
facet of the physician-investigator role, accepts a moral imperative to pursue a course
leading to the greatest benefit to the greatest number of individuals, even if the majority
of those individuals are not under his/her clinical care. The sponsor of the research has a
utilitarian interest in finding the investigational product which provides the greatest
benefit to the greatest number of patients, and to advance those treatments to approval.
Conversely, if the sponsor of the research is a corporation, this moral obligation is
conflicted by the corporate pursuit of approval to generate revenue from the treatment,
fulfilling the fiduciary responsibility that sponsor executives have to the corporate
shareholders. Priorities of the patient and the research has been largely mitigated by the
requirement of informed consent and the review and approval of the research protocol by
an independent ethics committee (National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research, 2016; International Council for
Harmonization, 2016).
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Contemporary Medical Research Ethics and Notable Cases of Transgression
In 1974, following the exposure of the ethical problems in the U.S. Public Health
Service’s Natural History of Syphilis study in Tuskegee Alabama, the National Research
Act was passed into law by the US Congress (National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research, 2016). The law created the
National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research, which was given the mandate to identify the basic ethical principles
and framework within which all biomedical and behavioral human subject research was
to be conducted (National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 2016). In 1978 the committee produced a
document titled; “The Ethical Principles and Guidelines for the Protection of Human
Subjects of Research” which is also termed the Belmont Report, after the Maryland
conference center where it was completed (National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research, 2016). The Belmont Report
was codified into the Code of Federal Regulations in 1979 and has also been referred to
as the Common Rule which has become the gold-standard by which human subject
research is conducted (National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 2016).
The Belmont Report outlined three fundamental principles which must be in place
for research to be considered ethical; Respect for Persons, Beneficence and Justice
(National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research, 2016). A fourth principle, non-maleficence is added to clarify
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minimization of risk and access to care if harmed while participating in research (Farisco,
Ferrigno, Petrini, & Rosmini, 2014). Each principle forms the foundation of several
elements necessary for the conduct of clinical trials today.
Table 3
Principles in Belmont Report and Application to Clinical Research
Principle
Respect for persons

Application
Autonomy must be respected, Participation is Voluntary,
Informed Consent must be obtained, and Researchers may not
deceive participants
Beneficence
A standard of no harm, maximization of benefits and minimizing
risks to each participant
Nonmaleficence
Assurance that intentional harm is prohibited, and that medical
care is available if participants are harmed during the research
Justice
Assurance of fairness in administration of study qualification,
and all study procedures, and assurance that all risks and benefits
are distributed fairly among all participants
Note. Adapted from National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research (2016)
Kant’s moral code forms the basis that requires the physician-investigator to
respect the research participant’s autonomy/free will by ensuring them that participation
in research is voluntary and refusing to participate does not impact the physician’s duty to
the patient or the quality of healthcare they provide (Kant, 2009). Furthermore, the
principle of justice ensures that risks and potential benefits of the research are distributed
fairly and equally amongst the participants. Thus, if there is a significant gap between the
number of countries where a new drug is approved and available, and the total number of
countries which provided research participants, the benefits of the research will not have
been distributed fairly and the principle of justice will have been violated. In the United
States, the FDA is not responsible for regulating drug prices for the drugs it approves, the
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drug manufacturers set their prices, which are then negotiated with various payers (such
as Medicare, Medicaid, Insurance Companies, HMOs and retail pharmacies). In other
regulatory jurisdictions, such as the EU, many member states have single-payer systems,
and therefore drug pricing is often part of the regulatory approval process. Since
globalization in clinical trials began its expansion into the developing world, examples of
questionably ethical practices, such as sponsor’s discontinuation of patients from
beneficial investigational treatment, and inappropriate placebo-controlled trials, several
international organizations have produced statements prospective planning for post-trial
access to treatment. It should be noted that none of these organizations are regulatory
agencies or national health authorities and therefore sponsors and physician-investigators
are not legally obligated to follow recommendations for providing a post-trial access plan
for investigational products deemed to be beneficial to all participants (MRCT, 2016). It
is also notable that in cases where investigational drugs are found to be safe and effective
in pivotal trials, removing patients from treatment may impose a risk of harm, especially
in cases where alternative treatments do not exist or are not available to the research
participant for other reasons e.g.; cost. In such cases, the forced discontinuation of
treatment would create a moral dilemma with the principle of non-maleficence and
potentially respect for persons if the participant had not been informed at trial initiation of
the possibility of benefit and removal of the benefit at the discretion of the study sponsor
(Grady, 2005).
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Table 4
Guidelines with Posttrial Access Statements
Organization/Document
Declaration of Helsinki
(2013)

Brief Statement
Sponsors, Researchers and Host-Country Governments should
make provisions for all participants who still need the
intervention if it is determined to be beneficial in the trial
CIOMS/WHO (2002)
Sponsors should continue to provide access to beneficial
interventions pending regulatory approval
United Nations (2005)
Host Countries and other stakeholders should provide new
diagnostic and therapeutic modalities or products stemming
from research and support for health services
UN AIDS (2012)
Stakeholders should ensure that participants who are infected
during a prevention trial are provided access to treatment
regimens from among those internationally recognized as
optimal. Agreement to do so should be sought in advance of
the trial
Nuffield Council (2005) Researchers should endeavor, before trial initiation to secure
post-trial access to effective interventions for participants in
the trial and that the lack of such arrangements should have to
be justified with the ethics committee
Note. Adapted from MRCT (2015)

Historically, the adoption of newly codified ethics practices in human subject
research indicates that caution is recommended as expansion in the number of
investigators, subjects, research protocols and participating countries in human subject
research occurs (Angell, 1997; Emanuel et al., 2000; Farisco et al., 2014; N. Kass, 2014;
Lurie & Wolfe, 1997). The Nuremburg Code, a foundation for the modern requirements
of informed consent and institutional ethical review of human medical research was
issued in August 1947, and took decades to become fully adopted, even among respected
institutions and clinical researchers in the United States (Mulford, 1967; OHRP, 2016).
Excursions from the code occurred after 1947, in some cases for decades, by academic
researchers, the US Public Health Service (USPHS), the NIH, the CDC, and others
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(Angell, 1997; Lurie & Wolfe, 1997; Msamanga & Fawzi, 1997; Reverby, 2001). These
ethical transgressions were sometimes egregious, as Beecher, Lurie & Wolfe, Reverby
and Walter emphasize in their reviews of published human studies (Beecher, 1966; Lurie
& Wolfe, 1997; Reverby, 2014; Walter, 2012).
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Table 5
Notable Ethical Transgressions in Clinical Research
Event (Date)
U.K. - Nuffield Prison/St
James Orphanage (1721)
U.S. - Natural History of
Syphilis (1934-72)
Germany- Nazi doctors
(1940-45)
U.S. Statesville Prison
malaria experiments (1942)
U.S./Guatemala – USPHS
STD experiments (1946)
U.S. Ohio State Prison,
Sloan Kettering, and Jewish
Chronic Disease Hospital
(1960-64)
U.S. Willowbrook School
(1956-70)
Uganda/U.S. vertical
transmission antiretroviral
trials (1994-96)

Primary Principle Violated
Respect for persons, Autonomy, Nonmaleficence
Respect for persons, Beneficence, Nonmaleficence, Justice
Respect for persons, Beneficence, Nonmaleficence
Respect for persons
Respect for persons, Beneficence, Nonmaleficence
Respect for persons, Beneficence, Nonmaleficence

Respect for persons, Nonmaleficence
Nonmaleficence, Beneficence, Justice
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Brief Summary of the U.S. Food and Drug Administration History
The FDA has a broad purview to regulate food, drugs, and medical devices. The
division regulating new drug approvals for pharmaceutical products is the Center for
Drug Evaluation and Research (CDER) and is comprised of 14 special divisions
corresponding to the areas of medical specialty for the majority of new drug indications.
In parallel, the FDA has the Center for Biologics Evaluation and Research (CBER),
arranged in similar therapeutic divisions. Finally, the Center for Devices and Radiologic
Health (CDRH) is responsible for the review and approval of all medical devices and
radiation emitting products (Van Norman, 2016b). The FDA has, since its departure as a
section of the U.S. patent office in the mid-19th century, has had the purview to evaluate
whether drugs were working in the manner they were advertised (U.S. FDA, 2018b). In
1938, the year following the contamination of a sulfanilamide elixir with ethylene glycol,
which resulted in the deaths of more than 100 patients, the Federal Food, Drug and
Cosmetics act was passed, which gave the FDA broader powers to ensure the safety as
well as the claimed efficacy of drugs (Van Norman, 2016b). In 1962, the FDA was given
additional powers with the passage of the Kefauver-Harris Act (KHA) (Greene &
Podolsky, 2012). The KHA gave the FDA a mandate to assess the efficacy, monitor the
accuracy of pharmaceutical advertising claims, and established the tradition of requiring
adequate, well-controlled e.g.; randomized, placebo-controlled trials, prior to the drug’s
approval for marketing (Greene & Podolsky, 2012). The 3-phase approach to clinical
drug development initiated with the KHA in 1962 remains the gold standard today, as
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does the standard for demonstration of efficacy and safety, the randomized-controlled
trial (Bothwell & Podolsky, 2016; Van Norman, 2016b).
Though the KHA was viewed as a barrier by the pharmaceutical industry and the
American Medical Association, it had significant public support following the tragic,
disfiguring and disabling teratogenic effects which occurred after expectant mothers had
taken the drug thalidomide, an anti-emetic, administered during pregnancy (U.S. FDA,
2014b; Greene & Podolsky, 2012). Thalidomide had not yet been approved for use in the
United States, however, approximately 10,000 children in 46 countries were affected and
both public and regulatory consciousness was raised about possible teratogenic effects of
prescription drugs (U.S. FDA, 2014b). The KHA granted the FDA both prospective, for
drugs in development, and mandated a retrospective review and approval for drugs
already approved between 1938 and 1962 (Greene & Podolsky, 2012; Van Norman,
2016b). A result of the KHA mandated retrospective reviews was the removal of more
than 600 drugs from the market for objective lack of efficacy (Greene & Podolsky, 2012).
By granting the FDA the power to prospectively and retrospectively demand proof of
safety and efficacy, the agency became backlogged, and by the mid 1970’s, the U.K.
pharmaceutical market began to observe a difference between both the speed of new drug
approvals, and the subsequent differences in their national formularies versus the
approved US formulary; the time difference associated with the difference in formularies
was termed “drug-lag” (Wardell, 1973; Wileman & Mishra, 2010).
The FDA initially denied the existence of a significant drug-lag, but ultimately the
shorter review and approval times and the increasing number of new drugs available on
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the United Kingdom formulary versus the United States, became clear to regulators and
clinicians (Van Norman, 2016b; Wardell, 1973). The observed drug-lag inspired
significant discussion in clinicians’ professional circles in the 1980s, particularly in
infectious diseases, due to the magnitude and severity of AIDS epidemic and the
complete lack of treatment options (Klein, 2017). Highly visible advocacy for AIDS
treatment, and convincing arguments allowing acceptance of surrogate endpoints; e.g.;
reductions in viral load ultimately led to the approval of Zivoduvine (AZT) in 1987, 7years after from the first publication of HIV/AIDS case studies (Greene & Podolsky,
2012; Kinch et al., 2014). Significant drug-lag was also noted in psychiatry and
cardiology in the United Kingdom versus the United States during the 1980s, as
practitioners called for reduction in review times and to increase the number of drugs
available for treatment of chronic non-communicable conditions as well (Vinar, Klein,
Potter, & Gause, 1991). It is important to note that in the 1980s and early 1990s,
academics and practitioners were more concerned with the therapeutic gap that drug-lag
created, whereas the pharmaceutical industry was more concerned over protracted review
times and uncertainty of review outcomes (Greene & Podolsky, 2012). At the time,
neither were concerned about the lag-time for international clinical trial participants to
receive access to new drugs, as the globalization of industry-sponsored clinical trials had
not yet begun its ascent to today’s prevalence (Tufts Center for the Study of Drug
Development, 2009).
These discussions ultimately led the groundswell which inspired the FDA
modernization act, also known as PDUFA I, passed into law in 1992. PDUFA has been
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renewed 5 times, most recently in 2017 (U.S. FDA, 2012). The Prescription Drug User
Fee Act has been a significant overhaul to the FDA which requires the applicants for new
drug approvals to cost-share with the FDA by paying a filing fee as well as additional
fees during the drug review process (DHHS, 2017a). In fiscal year 2018, the PDUFA fees
are expected to generate approximately $900 million of the FDA’s $1.12 Bn budget, or
85% (DHHS, 2017a). Application fees for 2018 are $2.4 million for a full FDA review of
a new drug application (NDA) or biologic license application (BLA) that includes clinical
data (DHHS, 2017a). Such cost sharing by industry has allowed the FDA to modernize
technology, make additional hires and to engineer more efficient processes within and
between divisions and other regulatory agencies to allow data sharing and review
optimization (DHHS, 2017a). The FDA’s commitment under PDUFA was to reliably
complete standard and priority reviews on schedules of 10 and 6 months respectively, and
to eliminate drug-lag, particularly between the US, EU and Japan (U.S. FDA, 2012).
The funding from the user fees and review optimizations has allowed the FDA to
commit to increasing capacity and speed and to provide transparency on performance.
Since PDUFA I in 1992, the average standard NDA/BLA review time has been reduced
from more than 20 months to approximately 10 months, in 2016 (U.S. FDA, 2017d).
Likewise, priority reviews have been reduced from an average of 16 months in 1993, to 8
months is 2016 (U.S. FDA, 2017d). Increased and structured communications between
the FDA and sponsors was also a part of PDUFA I-V modernization, particularly relating
to the development of orphan and products for the treatment of rare diseases and diseases
with high unmet medical need . PDUFA I-V introduced more flexible trial and U.S. FDA
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review options for sponsors, as well as issuance of priority review vouncers as a reward
for developing drugs for rare diseases in pediatrics (U.S. FDA, 2014a). The drug lag
observed in the 1970s-early 1990s has also been addressed since initiation of PDUFA 1V, with 60% of the FDA approvals from 2016 being the first in the world, versus
approximately 10% first in world in 1993 (U.S. FDA, 2017d).
Phases and Objectives of Drug Development and U.S. Food and Drug
Administration Review

Figure 3. Drug development phases. Adapted from Van Norman (2016).

Figure 3 illustrates the process and objectives for each phase of clinical
development, which are similar globally (Van Norman, 2016b). Beginning with Phase 1,
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first in human trials, are most frequently in normal volunteers, and have the main
objective of safety, tolerability and to identify a general dose-range (Van Norman,
2016b). There are some exceptions, such as oncology and rare disease drugs which may
begin with patients, however the majority of Phase 1 trials are conducted in normal
volunteers (Van Norman, 2016b). Oncology, Orphan drug and rare diseases are special
cases Phase 1 and their development can be complicated by therapeutic misconceptions
by patients, especially those who have no treatment options except participation in a
clinical trial (Appelbaum et al., 2012). Phase 2 studies are the first trials in the patient
population of interest and are generally randomized, controlled trials conducted on one to
several countries and focused on establishing and understanding the safety and a doseresponse relationship between the drug and the parameter of interest e.g.; LDL
cholesterol for a lipid lowering drug or Hemoglobin A1c for a type 2 diabetes agent (U.S.
FDA, 2017a; Van Norman, 2016b). Phase 3 trials have the objective of studying the new
drug in the broadest population with the disease of interest and measuring it’s safety and
efficacy in a population most similar to the one in which the drug would be marketed
(Van Norman, 2016b). Phase 3 trials are usually large, randomized, controlled and
global, depending on the disease of interest (Van Norman, 2016b).
Many estimates and narratives exist about the development costs and probability
of approval of a new drug, once it enters clinical development and completes each phase
of development. Because development costs and success rates are considered trade
secrets, each must be interpreted with care based on the author’s affiliations. One group
has conducted a series of annual anonymized surveys of pharmaceutical companies in an
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attempt to estimate costs and probabilities of success in a consistent manner (DiMasi,
Grabowski, & Hansen, 2016). DiMasi, et al. estimated in 2016 that the cost to develop a
new drug are approximately $1.3Bn, with probabilities of approval, when completing
each phase of clinical development as follows: 31% of drugs entering Phase 1 will not
enter Phase 2, 70% of drugs entering Phase 2 will not enter Phase 3, and 70% of drugs
entering Phase 3 will not go on to file a new drug application (DiMasi et al., 2016). If a
drug files an NDA or BLA with the FDA however, the probability of approval in 2016
was approximately 85% (U.S. FDA, 2017c). Stated differently, roughly 90-95% of drugs
entering Phase 1 trials will not go on to be approved by the FDA as is illustrated with the
blue diamonds in figure 3 above (DiMasi et al., 2016).

Figure 4: General FDA review and approval types.
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Figure 4 illustrates the 3 general review categories that an application will be
reviewed under (U.S. FDA, 2014a). Since PDUFA I was enacted, the standard review
time is mandated to be 10 months from the date of the application, assuming the content
if the application is found to be acceptable (U.S. FDA, 2017d; Somerville & Kloda,
2015). Priority review and Fast Track designations are categories of prioritization where
the FDA deems the product as a significant improvement over the current therapies
and/or provides a treatment option where a significant unmet medical need exists
(Somerville & Kloda, 2015; Van Norman, 2016b). Priority and Fast track reviews are
intended to give the FDA review teams the internal mandate to deliver action within 4-6
months, and/or in a more expedient manner than the standard review (U.S. FDA, 2012;
Somerville & Kloda, 2015; Van Norman, 2016b). In 2015 and 2016, the FDA granted 17
and 20 priority reviews, respectively and completed all of them according to the
expedited timeline of 4-6 months (Kinch et al., 2014).
Prescription Drug User Fee Act Modernization Impact and Comparison to
European Union Process
FDA’s PDUFA 1-V have made a significant impact on the pharmaceutical and
biotechnology industries, catalyzing signficant growth in the US prescription drug market
since 1992 (Hartman et al., 2018). The greater organization, increased transparency and
legal mandates for completion reviews according to specific time-frames by the FDA
with PDUFA I-V have reduced the risks for new product development and catalyzed an
interest in filing NDAs and BLAs with the FDA first (DiMasi et al., 2016). While the EU
adopted similar efforts to both streamline and centralize the approval process for all
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member states in 1995, there remain four options for drug approvals in the EU: (a)
Centralized procedure, where each member state has representation and approval for all
EU member states is issued, (b) National Process, which is a specific state-by-state
process, (c) Mutual recognition, which ocurs when an EU member state has approved a
drug through their national process and applies for approval in another EU member state,
and (d) Decentrlaized procedure, a process allowing application for simultaneous
approval in more than one but not all EU member states (Van Norman, 2016a). In 2016,
Centralized procedure EU approval times were approximately 45 days longer than the
FDA’s on average.
Gaps in the Literature
My literature review identified four gaps relevant to this study. Those gaps
include: (1) few references to any association between the FDA’s modernization act,
beginning with PDUFA I in 1992, and the genesis of broad and rapid expansion of global
participation in clinical trials, (2) the paucity of clear roles and division of responsibilities
for physician-investigators, sponsors, regulators and ministries of health to all patients
and communities which participated in global pivotal trials, (3) a lack of quantitative
metrics for sponsors to ensure timely and sustained access to all host countries for NCEs
determined to be safe and effective by the FDA, and (4) an analysis of the time-lag
between development of new, and/or refinement of established ethical principles in
human subject research and their adoption by global practitioners, as evidenced by
continued ethical transgressions following seminal ethical guidance documents such as
the Nuremburg Code, the Declaration of Helsinki and the Belmont Report. Gap 1 relates
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to a probable stimulus for the rapid growth in international clinical research by U.S>
companies, Gap 2 relates to ambiguity in the role and scope of responsibilities for
physician-investigators, sponsors and regulators, and the lack of guidance and regulations
assigning responsibilities, Gap 3 describes the subsequent need for development and
reporting of metrics for global access to new drugs by sponsoring companies, and the
introduction of industry-wide best practices, and Gap 4 is related to the observed time lag
for adoption of newly established ethical practices by physician-investigators, sponsors
and regulators as evidenced by examples of transgressions in modern clinical research
occurring sometimes decades after clear guidance such as the Nuremberg Code, the
Belmont Report and the Declaration of Helsinki were published. Addressing gap 3 is the
primary objective of this study, which is to propose a time-based framework to evaluate
sponsor performance in making newly FDA approved NMEs available in all countries
which provided research subjects to pivotal trials.
Addressing the Literature Gap on Timely Global Availability and Access
The findings from this study, either alone or in combination other parameters of
sponsor compliance, such as timely peer-reviewed publication of study results will
inform the construction of an objective ethical compliance scorecard by which companies
can be evaluated by sponsors themselves, patients and advocates, physician-investigators,
ethics committees, host country ministries of health, policy-makers, other companies
considering international trials, regulatory agencies, and international health and
advocacy organizations (Miller et al., 2015). It is hoped that the results of both the
primary and secondary analyses will provide a picture of whether sponsoring companies
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are prioritizing access to all trial participants and their communities with the same or
similar levels of expediency. Any patterns of regional differences in access or expediency
by sponsor location, drug indication, host country demographics, or other covariates
which emerge will be valuable to host countries with respect to assurances they can
demand of present and future clinical trial sponsors. The results may permit international
health, professional and advocacy organizations such as the WHO, the WMA and the
United Nations to assess the performance of sponsors and to ensure that correctable
barriers do not exist in any host countries which demonstrate inequalities in access and/or
protracted times to local approval relative to FDA approvals. Other sponsoring
pharmaceutical and biotechnology corporations with corporate responsibility statements
that include patient access as a priority, such as the Danish biopharmaceutical company,
Novo-Nordisk, for example, may have significant interest in their performance on an
annual and drug-by-drug basis, and how their performance compares to other companies
both competing in the same markets as well as those conducting research in host
countries in different indications (Novo-Nordisk, 2018).
Definition of Terms
Important terms I have used in this study are defined as follows:
Accelerated approval: A type of FDA approval granted if a drug treats a serious
condition and shows early evidence of substantial improvement over existing therapies
through direct or surrogate endpoints (Somerville & Kloda, 2015). Accelerated approvals
are conditional and allow the drug to be marketed while trials confirming efficacy are
completed in the post-marketing setting (Somerville & Kloda, 2015).
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Approval: The affirmative outcome of a regulatory agency’s review (such as the
FDA’s) of a new drug application to grant a license to market a new product due to
demonstration of safety and efficacy in adequately controlled clinical trials (U.S. FDA,
2016).
Autonomy: The ability of competent subjects to make their own decisions be
recognized and respected, while also protecting the autonomy of the vulnerable by
preventing the imposition of unwanted decisions (Beauchamp & Childress, 2013;
Owonikoko, 2013; Varelius, 2006)
Average approval duration: An elapsed time between 366-730 days between
FDA approval and approval of the drug in all countries which participated in pivotal
trials.
Beneficence: The philosophy of do no harm while maximizing benefits for the
research project and minimizing risks to the research subjects (National Commission for
the Protection of Human Subjects of Biomedical and Behavioral Research, 2016).
Breakthrough therapy: Breakthrough therapy is defined as a drug, used alone or
in combination with another drug, intended to treat a serious or life-threatening condition,
demonstrates a substantial improvement in one or more clinical endpoints based on early
clinical information (U.S. FDA, 2014a; Somerville & Kloda, 2015).
Clinical trial: A research study in which one or more human participants are
prospectively assigned to one or more interventions; which may include placebo or other
control; to evaluate the effects of those interventions on health-related biomedical or
behavioral outcomes (NIH, 2017b).
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Corporate fiduciary responsibility: duties in a corporate setting require directors
to apply their best business judgment, to act in good faith, and to promote the best
interests of the corporation (Poitras, 2009).
Delayed approval time: An approval duration of greater than 731 days but less
than 1826 days since FDA approval of a particular NME.
Drug-lag: Any delay in making a drug available in a particular market relative to
approval in a reference market, such as FDA approval in the United States. (Wileman &
Mishra, 2010)
Equipoise (clinical): The existence of a legitimate scientific question as to
whether the standard treatment or an investigational treatment is superior (Freedman,
1987).
Expedient approval time: A duration of 1-365 elapsed days between FDA
approval of an NME, and approval in all countries contributing patients in pivotal clinical
trials.
Fast-track review: A type of FDA review that allows applications to be made in a
piecemeal fashion; reserved for drugs intended to treat serious conditions with a high
unmet medical need (U.S. FDA, 2014a; Somerville & Kloda, 2015).
Investigational product: A pharmaceutical form of an active ingredient or placebo
being tested or used as a reference in a clinical trial; in FDA regulations,
an investigational new drug is any substance (such as a drug, vaccine, or
biological product) for which FDA approval is being sought (ICH, 2016).
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Justice: Ensuring reasonable, non-exploitative, and well-considered procedures
are administered fairly; the fair distribution of costs and benefits to potential research
participants (National Commission for the Protection of Human Subjects of Biomedical
and Behavioral Research, 2016)
New molecular entity (NME): A drug that contains an active moiety that has never
been approved by the FDA or marketed in the United States (U.S. FDA, 2014a)
Nonmaleficence: To do no harm; e.g.; Physician-investigators must refrain from
providing ineffective treatments or acting with malice toward patients (National
Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research, 2016)
Orphan indication: Diseases which affect fewer than 200,000 persons in the
United States or, if more than 200,000 persons, indications for which there is not a
reasonable expectation that U.S. sales will recuperate the development costs of the drug
(U.S. FDA, 2013)
PDUFA I-VI: The Prescription Drug User Fee Act, the first version of which was
passed into law in 1992, with the objectives of modernizing the FDA’s technology,
speeding its review process, increasing its capacity and improving transparency for
review and approval of new drugs (U.S. FDA, 2012).
Physician: A skilled professional trained and licensed to practice medicine;
specifically, an individual possessing a doctor of allopathic or osteopathic medicine.
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Physician-investigator: An individual who actually conducts a clinical
investigation and under whose immediate direction an investigational agent (drug) is
administered to a patient (U.S. FDA, 2017b; Schafer, 2010).
Physician-patient fiduciary relationship: A responsibility established between
physicians and patients, implicitly or explicitly, in which both agree to allocate to
clinicians discretion, the ability to act on patients’ behalf with respect to their health
(Lázaro-Muñoz, 2014).
Priority review: A type of FDA review that is 6 months in duration, and requires
that the drug has potential to treat a serious condition and represents a significant
improvement in current treatment, if any (U.S. FDA, 2013).
Respect for persons: Protecting the autonomy of all people and treating them with
courtesy and respect and allowing for informed consent. Researchers must be truthful and
conduct no deception (National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 2016).
Severely Delayed approval time: A duration of 1826 or greater elapsed days
between FDA approval and drug approval in all countries participating in pivotal trials
for a particular NME.
Standard FDA review: Ten months in duration, with no requirements for rare or
serious diseases or unmet medical need (U.S. FDA, 2013).
Therapeutic misconception: The belief that the purpose of a clinical trial is to
benefit the individual patient rather than to gather data for the purpose of contributing to
scientific knowledge (Appelbaum et al., 2012).
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Assumptions
The main assumptions I made for the data collection and the conduct of this study
were that the data available from the secondary sources, primarily from the various FDA,
EMA, PMDA and clincialtrials.gov websites and reports were accurate. Additionally, in
the case of the CIRS source of secondary data, where aggregated reports on comparative
drug approvals resides, the same assumption of accuracy was made. Finally, in cases
where necessary data were not available on public regulatory or non-profit websites; e.g.;
if a sponsor was contacted directly to determine approval date of a product in a specific
country, reporting of their responses assumed the sponsors’ report to a consumer’s
inquiry are accurate.
Scope and Delimitation
The intent of this study was to generate a categorical method for assessing the lagtime between approval of NMEs in the United States, and all countries contributing
pivotal human clinical trial data to new drug applications upon which FDA approvals
were based between 2006-2015. I also provide an analysis of several covariates and an
assessment of their impact on expediency of drug approvals in all countries which hosted
pivotal clinical trials. The primary analysis, and analyses of covariates serve as surrogates
for understanding whether the potential for exploitation of patients by foreign sponsoring
companies conducting global clinical trials exists in certain circumstances. Secondary
data from public websites of the FDA and other regulatory agencies, the NIH, non-profit
organizations and a free trial of a subscription-based data aggregating service were used
to calculate the magnitude of drug-lag, in months. Delimitation of the study is that the
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approval date in a particular country does not fully indicate whether a product is available
to the patients who need it, e.g.; it is possible that the drug is approved but not yet
reimbursed by the health system, that it is not and may never be reimbursed and therefore
both not affordable and unavailable to patients, or that other considerations exist which
make the approved drug unavailable in all countries which participated in development. It
is possible that myriad factors influence the time to approval on a region-by-region or
country-by-country basis which are not generalizable across borders; and an in-depth
analysis of those factors is beyond the scope of this study. The time-based nature of the
primary and secondary research questions gives credibility to the generalizability of the
results, however, the single perspective, e.g.; the approval date by the FDA relative to all
other countries is a known limitation.
Significance
Post-trial access to safe and effective medications tested in host countries is a
fundamental of global bioethics codified in the WHO, UNAIDS, Council for
International Organizations of Medical Sciences, guidelines as well as the Declaration of
Helsinki (Pace et al., 2006; WMA, 2013). However, legal or jurisdictional requirements
to register all drugs found to be safe and effective in countries providing research subjects
are uncommon and if post-trial access is provided to subjects, it is sporadic and shortterm (Chieffi et al., 2017; Dainesi & Goldbaum, 2012). Furthermore, trial sponsors are
under no legal requirement to offer expanded access to patients in all countries who
participated in their clinical trials, nor is there an academic, regulatory or industry
framework for contemplating the success scenario of drug approval in the United States,
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EU or Japan, and how to prioritize drug access for all countries providing research
participants (Darrow et al., 2015). Because no legal requirement exists, the frequency and
speed of this short and long-term access post-FDA approval is un-reported by sponsors
(Grady, 2005; Sofaer et al., 2009).
This investigation is unique in its examination of the time-lag from FDA drug
approval to complete availability of the new drug in all countries which provided
research subjects to pivotal trials. The purpose of this study was to assess, for the first
time, the frequency and timing of access to U.S. approved NMEs in all countries
contributing research participants to pivotal trials supporting U.S. FDA approvals
between 2006 and 2015. The primary assessment determined, relative to U.S. approval,
whether sponsoring companies sought and received marketing approval in all other
countries contributing patients to pivotal trials according to a four-category scale of
expediency (Expedient, Average, Delayed, Severely Delayed). Having data on the
expediency of by-country approvals for individual drugs relative to FDA approvals
provides a metric of transparency and justice to research subjects in all countries,
ministries of health, physician-investigators, regulatory agencies, policy makers and
current and future sponsors and contract research organizations which does not currently
exist. The research also considered FDA-specific covariates such as orphan indication,
and the type of FDA review such as standard or priority review and their impact on
global approval and availability of NMEs. Other covariates such as the drug indication,
headquarters location, maturity and capitalization of sponsor companies, and host country
incomes were examined for effects on timing to availability of the treatment in all
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countries which provided research subjects for NMEs approved in the United States
between 2006 and 2015.
Summary and Conclusion
Results from this study provide an objective measurement of sponsor performance
for ensuring access to all research participants, their communities, and host countries that
did not previously exist. The results of this study add to the transparency with which
sponsors of clinical research conduct themselves, similar to the 2007 FDA mandate for
sponsors to register all trials and to publish trial results on clinicaltrials.gov (NIH, 2017a).
The significance or ubiquity with which the results of this study may be considered
meaningful and result in action across various stakeholders is unclear without a mandate
from a powerful health authority such as the FDA, EMA or PMDA.
Currently, there exists a role and responsibility ambiguity between sponsors,
physician-investigators, ministries of health, ethics committees and other stakeholders for
prioritizing assurance of access to drugs for communities and individuals who bore the
risks to test them before the new drug was confirmed to be safe and effective.
International committees and non-profit organizations such as CIOMS, UNAIDS, the
WMA, the U.S. National Bioethics Advisory Committee, and the Nuffield Council on
Bioethics all clearly endorse prospective planning and disclosure of plans for post-trial
access prior to initiation of a clinical trial (NBAC, 2001a; UNAIDS, 2012; WMA, 2013).
Ambiguities lie in the parties holding primary responsibility for assessing and
maintaining compliance with the pre-trial plan, particularly in resource constrained
LMICs. Further ambiguities regarding duration of access, and to whom the drug access is
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to be provided, e.g.; to research participants only, or to community members in need who
supported the researchers and participants also exist and must be resolved fairly.
Additionally, the recommendations for post-trial planning have been interpreted in a
short-term context, versus a permanent one. Ensuring that the sponsor seeks local
approval for the new treatment, at a locally indexed affordable price, as soon as possible
following the FDA’s approval of the NME is the most just and sustainable approach.
Alternative approaches such as drug access funds, support of local healthcare
infrastructure and other solutions may be acceptable, however a trusted, unbiased and
systematic mechanism for evaluation and administration is necessary.
Seeking local approval places a specific burden on the sponsor, and there may be
myriad business, logistic or other reasons why sponsors may choose to prioritize seeking
approval in some countries versus others. Conceivably, those reasons could be related to
prediction of low to no revenue from the host country, or the host country’s economic
position, the amount of intellectual property (IP) risk the sponsor perceives in the host
country, the sponsor’s perception of logistics in making the drug available in a nonresearch setting, among many other considerations.
In conclusion, if adoption of approval expediency performance metrics was done
by sponsoring companies, or by the first approving regulatory agencies, which could
encourage sponsors to prioritize expedient and equal access to all host countries in the
most affordable manner plausible, that would be a significant positive global social
change. Establishment of additional transparency into sponsor company practices and
justice for all who have both directly participated in and hosted clinical research in their
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communities would be beneficial to the former group, and both beneficial to and
welcomed by the latter. Introduction of practices that unite global communities and
sponsoring companies in a mutual belief in improving global health and advancing global
justice simultaneously are plausible with prioritization and cooperation. Once roles and
priorities are established, advancing both global justice and health will likely be both selffulfilling and self-sustaining.
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Section 2: Research Design and Data Collection
Introduction
Global participation in clinical trials has increased since the 1990s, with 69% of
patients included in the FDA’s new drug approvals for 2015 recruited outside the United
States (U.S. FDA, 2017a; Kinch et al., 2014; Tufts Center for the Study of Drug
Development, 2009). This increased participation includes patients from the developing
world, whose countries have variability in the establishment, function, and oversight of
the components necessary to ensure proper ethical conduct of research with human
subjects (Angell, 1997; Emanuel et al., 2004). This rapid growth in globalization of
clinical trials has led to ambiguity in allocation of responsibilities for assurance of
posttrial access to effective medications. These ambiguities exist between the roles of
sponsors themselves, physician-investigators, ministries of health, ethics committees, and
agencies responsible for new drug approvals, and there is little data on how research
sponsors prioritize the continued treatment of participants whose trial data established the
safety and efficacy of NMEs (Angell, 1997; Annas, 2009; Miller et al., 2017). Little data
exist summarizing proportions of patients continuing treatment through extension trials,
or via sponsor investment in healthcare infrastructure of host countries or though sponsor
investment in drug access funds or through sponsors seeking approval in all countries that
contributed patients with equal priority as they do in the United States, EU, and Japan
(Banerjee et al., 2010; Prasad et al., 2016; Pratt et al., 2012).
The purpose of this study was to evaluate, based on publicly available
information, the priority with which sponsors gained approval in all countries that hosted
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clinical trials deemed pivotal for FDA approval between the years 2006 and 2015. The
data from this study complement existing data sets and their assessment of clinical trial
transparency through measurement of frequency and timing of clinical trial publications
(Miller et al., 2017). Utilization of the primary outcome data provides an indicator of
corporate prioritization of global health based on the expediency with which companies
pursue approval in all countries that hosted pivotal clinical trials. Knowledge generated
from this analysis may guide sponsors and key stakeholders in host counties such as
physician-investigators, ethics committees, and ministries of health in planning for the
posttrial period and engaging the best methods to ensure that all host populations benefit
from NMEs found to be beneficial in all communities that took the risks to test them.
Also, knowledge generated from this study contributes to a heretofore nonexistent
component of an ethical scorecard for pharmaceutical companies, as proposed by Miller
et al. (2017). Further, I completed analysis of covariates such as year of approval, drug
indication, orphan designation, sponsor characteristics, type of review, and host country
income that may influence the expediency of drug approvals in all countries hosting
pivotal clinical trials. Knowledge generated from the analysis of covariates provides
insight into how sponsor companies, physician investigators, ethics committees,
ministries of health, regulatory agencies, and policy makers can minimize gaps in
availability of new drugs to research participants.
The primary research question was addressed through a review of FDA NME
approvals for the years 2006-2015. The population of interest was identified from the
NME approvals between the years 2006 and 2015 in which the FDA’s approval was the
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first in the world. These data are available on the FDA’s annual drug approvals website
for NMEs. For the subset of NMEs for which the FDA is first in world approval and
those that included international patients in pivotal clinical trials, I calculated the time-lag
in months from the date of the U.S. approval to the date of approval in the last host
country. Any time-lag was coded into one of four elapsed time-based categories;
expedient, average, delayed, or severely delayed. I assessed covariates with regard to
whether they impacted the category of any observed time-lags.
In this section, I describe the study design, rationale, and methods. I identify the
study population and present the strategies for any sampling and filtering. I also describe
the process of data collection, coding, and management as well as the data analysis plan.
This section includes summaries of the quantitative descriptive and inferential statistical
methods used to test hypotheses for the primary research question and analyses of the
relevant covariates for the secondary research question. This section includes ethical
procedures and addresses both internal and external threats to validity. I used data from
the FDA’s Annual NME approvals database, as well as FDA summary bases of approvals
to provide the population for the primary analysis. I identified those therapeutic NMEs
approved by the FDA between 2006 and 2015 that included data from ex-U.S. subjects
and collected information for the drug approval in each participating country from
sources including but not limited to, the EMA website, the PMDA website, websites of
other local ministries of health for participating countries, sponsors themselves, and a free
subscription to a pharmaceutical data aggregator hosted by Springer Publications for
approval dates for each drug of interest in each country of interest. I utilized public
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databases such as Clinicaltrials.gov for confirmation of details, such as enrollment-bycountry and start and completion dates of various clinical trials that were not available in
regulatory databases.
Research Design and Rationale
This study was a quantitative study investigating first prevalence and second
magnitude of differences between the independent variables and the dependent variable.
This was an analysis of secondary data retrieved from the annual NME approval reports
from the FDA between 2006 and 2015. For the primary research question, independent
variables were regulatory approvals in each country providing patients to pivotal trials for
drugs receiving FDA approval between 2006 and 2015. The dependent variable for the
primary research question was time, more specifically, time-lag in months between those
drugs that received first-in-world approval by the FDA. Following the primary analysis in
research question 1, an inferential analysis of the dependent variable, drug-lag, was
performed which compared the drug-lag across regions to each other and tested any
differences for significance. In research question 2, I analyzed additional independent
variables including year of FDA approval, drug indication, orphan designation, FDA
review type, sponsor company location and market capitalization, and host country
income to test for any association between independent variables to the coded gradations
in the time lag between U.S. and each host country’s drug approval.
Collection and analysis of quantitative data was the appropriate methodology to
answer the primary research question, which was to calculate prevalence and time
differences between first NME approvals in the United States and their subsequent

74
approvals in all countries that hosted pivotal clinical trials between 2006 and 2015.
Collection of quantitative data from the annual NME approval reports from the FDA,
EMA, PMDA, and ministries of health from participating countries was efficient, simple,
and required limited resources to collect and transform data types. I determined
quantitative data and quantitative methods for analysis to be most appropriate to
investigate these research questions because they are clear, precise, numeric, and
objective (Creswell, 2014). Some quantitative data were further transformed into
semiquantitative, ordinal levels of measurement consistently, and these further
transformations conferred greater meaning to and interpretation of the outcomes through
both descriptive and inferential statistical analyses (Creswell, 2014; Frankfort-Nachmias
& Nachmias, 2008). Frequency distributions, magnitudes of differences, hypothesis
testing, and exploration of associations between independent variables and the dependent
variable, time, for the secondary research questions were all possible because these data
were quantitative.
Related research regarding company transparency in publications of clinical trials,
such as studies by Miller et al. (2017) and Viergever & Li (2015), used quantitative data
and descriptive statistics to summarize the frequencies and times to compliance by
pharmaceutical companies with trial registration regulations and publication guidelines
established both by the NIH and the International Council of Medical Journal Editors
(ICMJE), respectively (National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 2017b; ICMJE, 2018; Miller et al., 2017;
Viergever & Li, 2015). Miller and colleagues (2017) attempted to construct a compliance
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and transparency scorecard based on adherence to FDA regulations for registration and
updating the clinicaltrials.gov trial registry and adherence to the publication guidance
offered by ICMJE as a surrogate for transparency. This research applied a similar
approach through quantitative analysis of whether sponsoring companies were honoring
statements in guidance documents issued by WMA, CIOMS, UNAIDS, NBAC, and the
NCOB pertaining to posttrial availability of newly approved drugs to all participants in
all countries.
The research questions and their associated hypotheses were as follows:
RQ1: Of the NME’s first approved by the FDA between 2006 and 2015 that
included foreign patients in pivotal trials, what proportion of sponsoring
companies achieved expedient approval in all participating countries?
H01: Fewer than 66% of drugs were expediently approved (within 1 year of
FDA approval) in all host countries.
Ha1: 66% or more of drugs were expediently approved (within 1 year of FDA
approval) in all host countries.
RQ1a (Inferential analysis): Are the observed regional drug-lags of U.S.-EU,
U.S.-last country, EU-last country and a simulated 24-month U.S.-last country
matched pairs different from each other?
Ho1b: No difference exists in drug-lag between matched pairs U.S.-EU, USLC, EU-LC and U.S.-24
Ha1b: A difference exists in drug-lag between matched pairs U.S.-EU, USLC, EU-LC and U.S-24
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RQ2: Are covariates of year of U.S. approval year, drug indication, orphan
designation, FDA review type, host country characteristics and sponsor company
characteristics associated with specific approval time categories (expedient,
average, delayed, or severely delayed) in all host countries?
H02: Covariate types are not associated with specific approval time categories
in all host countries (expedient, average, delayed, severely delayed).
Ha2: Covariate types are associated with specific approval time categories in
all host countries (expedient, average, delayed, severely delayed).
Each of the seven covariates was tested for association with an elapsed time range
from FDA approval, which has been coded into the four expediency categories, yielding
a binary outcome of: (a) associated or (b) not associated. The threshold for assigning
association to the outcome was frequency of co-occurrence of independent and dependent
variable in 50% or greater of cases (Hinkle, Wiersma, & Jurs, 2003). Strong positive
associations are considered present if the frequency of co-occurrence of independent and
dependent variables occurs in 70% or more of cases and strong negative associations are
considered if dependent and independent variables co-occur in 30% or fewer cases
(Hinkle et al., 2003). Associated outcomes, whether positive or negative, are reported as
such.
Methodology
Population, Sampling Procedures, and Data Collection Methods
Population. The overall target population was the total number of NME
approvals completed by the U.S. Food and Drug Administration for calendar years 2006
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through 2015 inclusive. Excluded from the data set of annual FDA approvals during that
period were generic drugs, biosimilars and medical devices, none of which qualify as
NMEs. Approvals of a simultaneous or second indications for already approved NMEs in
the same year are excluded from the data set, as were those NMEs for which the FDA’s
approval is not the first in the world. The choice of the time frame (2006-2015 inclusive)
was made because it provided a decade of approvals data during a period of expansion
both in the number of countries participating in clinical trials, but also in the proportion
of ex-US versus U.S. patients included in each application for FDA approval (U.S. FDA,
2017a; Tufts Center for the Study of Drug Development, 2009). The choice of both the
U.S. FDA as the regulatory agency, and of an NME’s first approval in the United States
allowed discrete and quantitative benchmarking of US approval dates versus the approval
dates in each country providing patients to pivotal trials.
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Figure 5. Population sample from FDA approvals 2006-2015.

Sampling frame. All data collection and analysis in this study were sampled
from secondary data sets on drug approvals housed primarily on the U.S. FDA’s public
websites. Figure 5 describes the filtering of the overall FDA approval data set, to the
primary data set of interest for this study, e.g.; drugs first approved by the FDA between
2006-2015. Access to annual reports of all drug approvals in a PDF format are housed on
the public website of the FDA. Further details of the entire FDA review of each approved
drug are housed, also in a PDF format, in the summary basis of approval section of the
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FDA’s public website. The inclusion criteria for the sample data were the following: a)
the FDA approval must have occurred between the dates of January 1, 2006 and
December 31, 2015, b) the FDA approved molecule must meet the definition of an NME,
c) only one NME indication approval is counted if more than one indication is approved
either simultaneously or in the same year, e.g.; simultaneous approvals for different types
of non-Hodgkin lymphoma, and d) only those NME’s approved, where the pivotal trials
included any ex-US patients, and the FDA’s is the first in the world approval of the
NME.
While not present in each FDA annual approval report, data on the FDA’s first in
world approvals was compiled by a combination of public resources including FDA
division director status reports and annual reports on regulatory agency performance
compiled by the Centre for Innovation in Regulatory Science (CIRS), a United Kingdom
based non-profit organization which tracks comparative performance of drug regulatory
agencies. The former FDA Division Director, Dr. John Jenkins, was contacted via email
and provided on-line links to 2015 and 2016 updates, and no special permission was
necessary (J. Jenkins, personal communication, May 13, 2018). CIRS annual reports are
available on-line or via request. CIRS reports capturing the 2006-2015 period were
requested, and on-line links were provided by Dr. Magdalena Bujar of CIRS. If
necessary, for collection of necessary data for the primary research question, each
sponsoring company were contacted for the exact dates of approval for each drug in each
participating country if the approval dates are not provided on local health authority
public websites such as the EMA for EU countries, PMDA for Japan and/or other
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participating countries. Additional data, relating to the independent variables in the
secondary research questions were obtained from sources noted in Table 6.
Table 6
Independent Variable Details Research Question 2
Variable/Level of
measurement
Year of U.S. approval/
Ordinal
Drug indication/
Nominal
FDA review type
Nominal

Orphan designation
Nominal
Host country characteristics/
Ordinal
Sponsor company
characteristics/
Nominal

Data source
Calendar year of FDA approval is provided in each FDA
NME Annual Approval Summary Report available on the
FDA’s public website.
The specific approved indication is included in each FDA
NME Annual Approval Summary Report available on the
FDA’s public website.
The FDA review classification; Standard Review (10
months), Priority Review (6 months) and are included in
each FDA NME Annual Approval Summary Report
available on the FDA’s public website.
Orphan designation (under 200,000 patients in United
States) available on the FDA’s public website housing the
summary approval data for each individual NME.
World Bank Income Category; Low, Lower-Middle,
Upper-Middle, High is available, for each country, on the
World Bank’s public website.
Country of Headquarters, Publicly Traded or Private,
Market Capitalization at time of United States Approval
(if available), available on each company’s corporate
website and via NYSE or NASDAQ public records.

Each of the independent variables included in research question 2 is relevant to
the overall project because each conceivably influences the time to FDA approval for any
specific NME. For those variables not determined by the FDA itself, e.g.; host country
characteristics and sponsor company characteristics, each can exert influence over the
time taken to complete FDA review. Host country characteristics can, for example,
influence the time to completion of the FDA’s review if the reviewing division has no
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experience with patient data from that country and clinical sites have not been previously
inspected by FDA inspectors. Sponsoring company characteristics such as experience and
capitalization can influence both the time taken for FDA review, as well as the
prioritization, preparation and execution of approval filings in all participating countries.
Data access. The source for the primary data was the US Food and Drug
Administration’s annual NME approval reports are housed on the FDA’s public website
and are available for download in PDF format. These reports contain no confidential
information of the patient participants in clinical trials included for each NME, nor do
they contain any proprietary information of the approved drug’s sponsor or disclose
identities of drug structure and formulation or participating physician-investigators. The
content of each annual NME report includes the following elements: Application
Number, Proprietary drug name, Generic drug name, Applicant/Sponsor name,
Classification/type of review, Approval date and Approved indication for the NME. Data
for the Proprietary drug name, Applicant/Sponsor name, Classification of review type,
Approved indication and Approval date were entered into a master excel spreadsheet
containing all NMEs approved between calendar years 2006 and 2015 inclusive. The
completeness of the master spreadsheet was cross-checked against each year’s summary
report on the FDA, EMA and each participating country’s drug formulary websites, as
available. Individual tabs in the master excel spreadsheet were created to capture all data
elements required for each covariate summarized in Table 6 and manually entered.
Other sources for data relating to the covariates included in the secondary
research question were collected from two additional sources available on the FDA’s
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public website. Details of countries with sites included in the pivotal clinical trials were
collected from the Summary Approval section of the FDA’s public website for each
individual approved NME. Details on pivotal trials and any post-approval requirements
were manually entered into the appropriate tab in the master excel spreadsheet. Drug
approval dates for each individual country were obtained through public websites for
each country’s ministry of health, or, for countries which do not maintain these data on
public websites, the sponsoring company was contacted and their reported approval date
in each country was entered into the appropriate covariate tab in the data spreadsheet. In
cases where approval status and approval dates were not available, a free subscription to
a pharmaceutical data aggregating subscription, ADIS Insight, hosted by Springer
Publications was consulted and the data recorded in the master spreadsheet.
Sample size. The primary research question and the testing of the null and
alternative hypotheses were descriptive in nature and therefore a sample size calculation
was not necessary. Figure 4 illustrates the filtering of cases from the original number of
293 NME approvals to the analysis data set, which yielded an analysis data set of 157
therapeutic drugs first approved in the United States between 2006 and 2015. Because the
population for the primary and secondary research populations is therapeutic NMEs first
approved in the United States, an inferential analysis of the primary research question
was conducted using the European Union approval date of each NME, as a reference
point by calculating the numeric difference in months for each drug first approved in the
United States versus the approval date in the EU. The difference in approval date
between the first approval (United States), the intermediate approval (EU) and last host
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country approval (LC), measured in months, constitutes a measurement of “drug lag”,
which was inferentially analyzed for statistical significance via nonparametric rank tests
for paired samples from both the U.S. and EU approval date benchmarks.
The secondary research question examined associations between covariates and
approval dates in all countries included in pivotal trials. The chi-square test was chosen
for inferential analysis of nominal covariates. The sample size for this inferential analysis
was calculated based on an effect size of 0.5. An absolute value of 0.5 is the midpoint of
the r values (|0.3-0.7|) for which a correlation is considered moderate, be it positive or
negative (Glantz, 2012). At a power of 90% and statistical significance at the 0.05 level, a
minimum sample size of 43 was required to test the hypothesis for the secondary research
question which explored the associations between each covariate and any approval lag
between the United States and the last approval in the countries participating in each
drug’s pivotal trial (QFAB, 2018).
Data Collection Method
The broad study population sampled includes all NMEs approved by the U.S
Food and Drug Administration between January 1, 2006 and December 31, 2015. Figure
4 illustrates how the population sample was refined by selecting those NMEs, where the
FDA’s approval represented the first in world approval of that molecule for its first
approved indication. For example, if an NME was approved by the FDA for two different
indications in the same calendar year, the indication and date of the first approval was
selected and the second indication approval date was excluded, because, by definition,
the molecule no longer meets the definition of NME. The FDA annual NME approval
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reports for the years 2006-2015, available on the FDA’s public website contain the
entirety of drugs included in the sample for this study. Similarly, the drug approval dates
for those approved by the EMA were accessed from the EMA’s public website which
aggregates the same approval date and indication data.
Data Analysis Plan
SPSS was used for data analysis of the primary and all secondary research
questions. Hypotheses for primary and secondary research questions were tested with
descriptive versus inferential statistical methods. All descriptive statistics, including
measures of central tendency, frequencies, percentages and cross-tabulations were
performed by SPSS. All descriptive data outputs, including summaries, tables and graphs
were generated by SPSS and included as appropriate in the Results section with
interpretations.
With reference to the primary research question and to allow inferential analysis,
each drug’s approval date in the European Union was used as a reference. A Wilcoxon’s
Signed-Ranks test was conducted, comparing the drug-lag between the United States-EU,
the drug lag between EU approval and the last participating host country’s approval, an
adjusted United States-last host country approval and a simulated United States-24-month
drug lag population. Median lags between the United States-EU, the EU-last host country
approval, the U.S.-last host country and the simulated U.S.-24-month population were
assessed for statistical significance. Further inferential analysis of covariates included in
the secondary research question included a chi-square analysis for independence of
covariates to the observed categorical value for drug-lag between the U.S. approval and
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last participating country’s (LC) approval. All descriptive and an inferential analysis were
performed with SPSS.
Preparation of the data for analysis included a manual review and assessment of
completeness of values necessary to the primary research question. These elements
included the date of FDA approval and the dates of approval for the all countries included
in pivotal trials considered by the FDA to have been pivotal to their first approval of the
NME, between January 01, 2006 and December 31, 2015. The same manual missing data
review and assessment was performed for each covariate and the entire data set was
examined for patterns of missing data. No recognizable patters existed, and the SPSS
missing data, duplicate data and identification of unusual data functions were used to
programmatically interrogate the complete data set and report frequencies of missing
data, duplicate data and outliers were completed. An assumption that overall frequency of
missing data in the primary research question data set of less than 5%, was assumed to be
by chance. For the primary analysis, missing values were planned to be replaced with the
mean value for the lag-time variable in the data set, i.e. if the average lag-time between
U.S. and last country’s drug approval = 40.5 months, 40.5 will be entered for each
missing time value. Missing values for each covariate in each portion of the secondary
research question, because they are nominal, were planned to be replaced with the most
frequently occurring value in that data set if missing. For drugs approved by the FDA in
years 2014 and 2015, the status of approval in the last participating country was assessed
by a cutoff date of April 1, 2019.
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Descriptive analyses. Both the primary and secondary research questions are
addressed through application of descriptive statistical methods, because the null and
alternative hypotheses for both research questions are based on frequencies of time-based
categorical outcomes for the dependent variable. Descriptive statistical analysis was
conducted with SPSS, allowing frequencies, minimum-maximum range, with mean,
median and mode as measures of central tendency, and standard deviations. Descriptive
analysis also provided insight into whether the data are normally distributed, any patterns
and outliers present in the data set, visible as large dispersions or potentially through
other patterns. Large ranges, interquartile ranges and standard deviations can lead to false
precision for the measures of central tendency, especially in cases where smaller samples
are used to represent larger populations (Leicester, 2017). The 10 year time period for US
drug approvals between 2006-2015 used as a sample provides an adequate sample size to
conclude that any associations found between independent variables and the dependent
variable are not likely to be due to chance (Glantz, 2012).
Inferential analysis. The hypothesis in research question 1, which was answered
descriptively, is whether fewer than 66% of drugs first approved in the United States are
approved in all countries which hosted the pivotal clinical trials within 12 months of the
FDA’s approval. Following the descriptive analysis, and before coding the numeric
outcomes of the primary analysis to the four categories of expediency previously
referenced, inferential statistical methods were used to further investigate both the
magnitude of the time delay for drug approvals in the last host country between 2006 and
2015. Because this study’s sample considers only the NMEs first approved in the United
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States, the median approval delay, or drug lag, for the United States will be 0 months. To
account for this, the EU approval date for each NME during the 2006-2015 period was
added to the analysis as a reference population. A Wilcoxon Signed-Rank test was
performed to assess whether the approval delays in the last participating host country
versus the United States, and versus the EU as a reference population, are statistically
significantly different from each other. The Wilcoxon Signed-Rank test is a test used for
paired data and is used to assess the significance of the differences between the 2 groups
being tested, with the null hypothesis being that the medians of the 2 groups being tested
are the same (Glantz, 2012). This inferential analysis of the primary research question
sets up further investigation of which and to what extent the 7 covariates evaluated in the
secondary research question contribute to any observed delays in drug approval in EU
host countries, as well as the host country with the last chronologic approval.
Two proposed adjustments to correct for the median drug lag value of zero for the
United States were planned. First, adding the EU as reference population, because it
differs in approval date from the US FDA and will thus has a value greater than zero as
the calculated drug lag. Including the EU as a reference population also provides
additional information regarding the significance of the drug-lag for host countries both
inside and outside the premium priced United States and EU markets. Second, a
simulated median value of 12 months was proposed to be imputed for the U.S. drug lag,
and that value was to be tested for statistical significance against the median drug lag for
the last approved country which participated in each pivotal clinical trial for each U.S.
approved NME. The choice of 12 months for the imputed U.S. drug lag value in the final
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comparison corresponds to the expedient approval outcome category of the primary
research question, upon which the hypothesis is based. The results section includes an
adjustment to the simulated value from 12 months to 24 months, based on the observed
drug-lag values.
Table 7
Data Pairs for Testing in the Wilcoxon signed-rank test
Pairs for comparison
U.S. approval lag; approval in last host
country
U.S. approval lag; approval in European
Union
EU approval lag; approval in last host
country
U.S. approval lag + 24 months; approval in
last host country

Description
Median U.S. lag = 0 months; compared to
median months elapsed between U.S.
approval and approval in last host country
Median U.S. lag = 0 months; compared to
median months elapsed between U.S.
approval and approval in European Union
Median EU lag from U.S. approval in
months; compared to median host country
lag from U.S. approval in months
Simulated median value of 24 months
applied to U.S. approval lag; compared to
median months elapsed between U.S.
approval and last Host country approval

Table 7 shows the four paired Wilcoxon signed-rank tests to be performed to
assess the significance of the differences in approval times for the United States versus
the last host country approvals, the United States versus the EU approvals, the EU versus
last host country approvals, and the adjusted U.S. approval lag, versus the last host
country approval.
The magnitude or strength of associations between the 7 covariates included in
the secondary research question were assessed through inferential statistics. Each
covariate could exert either positive or negative influence over the dependent variable,
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time or approval expediency category between U.S. and last host country’s drug
approval, through logical or practical means. Using orphan indication status as an
example, granting of an orphan indication, i.e.; fewer than 200,000 cases in the United
States, can positively influence the FDA’s prioritization of the drug’s approval due to
high unmet medical need, which can influence other countries’ ministries of health in a
similar way to expedite approval in all countries which participated in the pivotal trials.
Conversely, orphan status of may cause companies to prioritize approvals in the higher
premium markets such as the United States, EU and Japan and not pursue approval in
countries with a small number of patients with the disease and less favorable drug
pricing, despite their having participated in pivotal clinical trials. This association was
examined using cross-tabulation of each covariate and the approval expediency category
calculated for each drug, e.g.; Expedient, Average, Delayed and Severely Delayed. A chisquare inferential analysis was conducted to assess each covariate’s positive or negative
level of association with any particular approval expediency category. Level of
association is determined by a minimum absolute value of |0.5-1|, as these considered a
moderate to strong linear association (Glantz, 2012). Chi-square values meeting an
absolute value criterion of 0.5 to 1 indicate that covariate as positive for influencing the
dependent variable in a directional nature, either positively, or negatively. The direction
of the association between covariates and the approval time category, positive or
negative, is reported.

90
Validity
Validity in research, stated broadly, is the ability of the investigator, through the
methods and instruments they employ, to demonstrate that what is being measured is
what was intended to be measured, that the methods support an accurate analysis of the
observations and measurements made, to an extent that they can be generalized to a
broader population (Frankfort-Nachmias & Nachmias, 2008). The investigator must
demonstrate that they considered and addressed significant areas where potential errors
with the data, issues with their analysis of the data, and other elements have been
minimized. Identification of areas where errors may encroach upon the validity of this
quantitative study are important because several independent variables are being assessed
for influence on the single dependent variable. Two ways in which the validity of this
study’s assessments can be questioned are: (1) to fail to consider, include and analyze an
important extraneous variable which may have a simultaneous and similar influence on
the dependent variable, as the independent variables of interest and (2) to fail to identify,
recognize and address a confounding variable, which is a variable influencing both the
independent and dependent variable, which can lead to false associations between
independent and dependent variable as well as false conclusions (Frankfort-Nachmias &
Nachmias, 2008; Glantz, 2012). Broadly, there are two types of threats to the validity of a
study; threats to internal validity and threats to external validity, each type is defined and
addressed in the forthcoming sections.
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Threats to Internal Validity
The definition of internal validity hinges on the requirement that the investigator
has considered, through the investigational design, mitigations or elimination of the
influence of factors on the dependent variable which are not included in the study
(Frankfort-Nachmias & Nachmias, 2008). Not doing so can cause false or inaccurate
inferences to be made, or to lead to inaccurate interpretations of the magnitude of
relationship or influence of independent variables on the dependent variable. Myriad
threats to internal validity in studies of secondary data sets exist, including the primary
concern that the methods used to collect the data were not prospectively designed to
address the specific research questions that the investigator conducting the secondary
analyses wishes to address (Cheng & Phillips, 2014). Related to this primary concern is
an inability to influence or improve the methods of the original study to contemporary
standards or to account for changes in terminology, definitions, or other differences
(Cheng & Phillips, 2014). If the methods of collection, definitions and measurements of
the primary data are not clearly documented, subsequent analyses by investigators
unaffiliated with the original data collection may introduce assumptions which can be
confounding (Cheng & Phillips, 2014). Because this investigation relies of data
emanating from public health authorities and relies on more absolute data points, such as
dates, specific drug names, specific countries, and standardized definitions, such as
World Bank income categories, the risks of nuance, changes or other impacts on the data
used for the primary and secondary analyses are minimal. The largest threat to internal
validity for this investigation lies in cases where primary data, such as drug approval
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dates in countries outside the United States or EU, are not present on public websites, and
thus reliance on individual inquiries to the sponsoring companies was required. These
data may be less reliable than data collected from publicly hosted government supported
websites, impacting the validity of the primary analyses conducted in this investigation.
Furthermore, because this investigation considered the time period of 2006-2015,
covariates such as country income categories and sponsoring company characteristics
may have changed over time, which is the primary reason for including calendar approval
year as a covariate in this investigation.
Threats to External Validity
External validity refers to the ability to extend, or generalize the results of the
investigation to the population level, or levels beyond the limits of the sample studied
(Frankfort-Nachmias & Nachmias, 2008). The data sets included, which provide the data
for the analyses of the primary and secondary research questions are nearly exclusively
aggregated and reported by neutral third parties, such as the U.S. Food and Drug
Administration, the EMA, the NIH, the Center for Innovation in Regulatory Sciences, the
World Bank and NASDAQ, and are therefore unlikely to contain systematic errors or
other types of bias which places limits on their validity or ability to be extrapolated. The
targeted secondary data, as they are hosted in each respective organizational database, are
deemed to be appropriate to answer the primary and secondary research questions
proposed for this study. The level of completeness of the data for samples drawn from
each hosted data set were evaluated for completeness, for a high proportion of outliers
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and internal logic through data cleaning methods described in the data analysis section
for this study.
Caution should be taken in generalizing the results of this study to countries
which did not participate in international pivotal trials for new molecular entities
approved by the FDA during the 2006-2015 period, as those are the limits of this sample.
Furthermore, differences found between regions in simultaneous or expedient approval in
all host countries through this analysis, it will be necessary to collect additional
information, within the scope of an additional study, to determine whether any corporate
or practical rationale influenced these observed outcomes.
Ethical Procedures
The sources for the data in this study, the U.S. FDA, the EMA, the CIRS data
reports, Clinicaltrials.gov, ADIS Insight and other ministry of health websites do not
contain personally identifiable, private or sensitive medical information, and are available
on the public websites previously listed. The data are available for public use and do not
require licenses from the agencies which publicly host the data. All individual data
contained within the FDA’s new drug applications (NDAs) and the EU’s product
marketing applications (PMAs) in order to be considered an acceptable submission to
these regulatory agencies, is completely de-identified, (ICH, 2016). The data for research
question 1 includes calendar dates, and the data for research question 2 relate to
covariates in the public domain which do not involve individuals and do not require
access of private, sensitive, protected or personally identifiable data, nor are any data of
these types necessary to complete the outlined analyses. Because the source raw data are

94
de-identified, any resulting data sets are generated after application of rigorous
submission standards by regulatory agencies and provided to the public only after a
thorough application of both data protection standards and data quality standards. Thus
these data sets have a very low risk of containing sensitive or identifiable information
considered to put individuals or groups of individuals at risk of being identified
(Tripathy, 2013).
The Walden University Institutional Review Board (IRB) granted approval prior
to completion of any analyses on these data. Data entry and quality standards were
applied to the data prior to its statistical analysis and application of data cleaning methods
for missing data, outliers and potentially spurious raw data were completed through SPSS
and manual data cleaning methods. Sharing of the results and study outcomes will be
done with Walden University IRB if required and with representatives of the FDA, the
EMA, and members from the Centers for Innovation in Regulatory Sciences, all of which
contributed raw data to this study. Publication of the results would occur with permission
of those agencies contributing raw data if required and, also if necessary, from the
Walden University IRB.
Summary
Section 2 includes a statement of the primary and secondary research questions,
the dependent and independent variables, the hypotheses tested and the descriptive and
inferential statistical methods. The secondary data sources and criteria for selection of
cases which ultimately comprised the sample for the research are also described. Methods
for data management, cleaning, manual data entry into Microsoft ExcelTM tabbed
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spreadsheets, from the secondary data sources and addressing missing data were
described. To be eligible for inclusion in the sample, the period of analysis was FDA
NME approvals over a calendar-decade, beginning on 01 January, 2006 through 31
December 2015. This choice of a 10-year period was prospectively made, versus defining
the sampling duration and resulting sample size based on a formal, pre-determined
sample size calculation. A description of any threats to internal and external validity are
presented, as are potential mitigations and strategies for minimization. A summary of the
ethical approval procedures followed both prior to data analysis and prior to publication,
if necessary, are described. The results of the descriptive and inferential statistical
analyses will be presented in Section 3.
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Section 3: Presentation of the Results and Findings
The primary purpose of this study was to evaluate, over a 10-year period, the time
to availability, or drug lag of newly FDA-approved drugs in all countries that hosted
clinical trials considered by the FDA as pivotal to the NME’s approval. Independent
variable covariates such as the year of approval, the drug’s primary indication, host
country income, sponsor company location and market capitalization, the priority
assigned by the FDA to the drug’s review, and whether the drug was granted orphan
designation were explored for an association with the magnitude of any observed drug
lag, the dependent variable. Review of the all NMEs approved by FDA between January
1, 2006, and December 31, 2015, demonstrated that the majority relied on clinical data
generated in multinational clinical trials. The FDA’s annual drug approvals (ADAs) and
each individual drug’s drug approval package (DAP) were the secondary data sources to
which the foundation of this research was benchmarked; both are available in PDF format
on the FDA’s website under drug approvals.
I calculated drug lag by sampling a subset of all approved NMEs during the 20062015 period obtained from the FDA’s ADAs for NMEs. The inclusion and exclusion
criteria limited the sample to include the following cases: FDA’s approval was the first in
the world for the product, the approved product was a therapeutic versus a diagnostic
agent, and ex-U.S. patients were included in trials deemed by the FDA as pivotal to the
product’s approval. The designation of a trial as pivotal was determined via a review of
the statistical review section in the FDA’s DAP documents for the NMEs approved
between January 1, 2006 and Dec 31, 2015.
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The increment in months between the FDA’s approval of a specific product and
the approval of that product in all countries that hosted pivotal trials is the individual
product’s drug-lag, and this was the primary outcome for the main research question. The
magnitude of drug-lag was measured in months and categorized into four time-based
categories, expedient approval, average approval, delayed approval and severely delayed
approval. The drug-lag periods in months assigned to each category were 0-12, 13-24,
25-60, and greater than 60 months, respectively.
Drug-lag can be calculated on several bases, and for the primary analysis I used
the most inclusive method, which was the time to known approval of the product in all
countries hosting pivotal clinical trials. In this study I calculated drug-lag in months on
the bases of (a) individual product drug-lag, that is, time from U.S. approval to approval
in last participating country; and (b) regional authority drug-lag, that is, time from FDA
approval to EU approval, or time from FDA and EU approvals to last-country approval,
for the purposes of comparison. Drug-lag data for the EU and all host countries were
collected from government ministry of health websites, public press releases, sponsor
company inquiries and other free, internet-based sources from which specific country
drug approval dates could be verified. For this study I also considered as secondary
research questions the following covariates for association with the dependent variable,
drug-lag: year of approval, approved indication, sponsor company characteristics of
market cap and world headquarters, the World Bank economic category of host countries,
the orphan-drug status granted by FDA, and whether priority or standard review was
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granted by the FDA. The research questions and their associated hypotheses are as
follows:
RQ1: Of the NME’s first approved by the FDA between 2006 and 2015 that
included ex-U.S. patients in pivotal trials, what proportion of drugs achieved
expedient approval/drug-lag of 0-12 months in all participating countries?
The dependent variable for the primary research question was the percentage of
individual products with an expedient individual product drug-lag category (i.e., 12
months or less), and the independent variable of time measured in months.
H01: Fewer than 66% of drugs were expediently approved (within 12 months
of FDA approval) in all host countries.
Ha1: 66% or more of drugs were expediently approved (within 12 months of
FDA approval) in all host countries.
I then performed an inferential analysis of RQ1 to assess whether a difference
exists in the drug-lag between the U.S.-EU, U.S.-LC, and the EU-LC pairs. A fourth,
simulated group called U.S.-24 was added for comparison to the U.S.-LC group to
simulate a case, for example where the EU approved a product first and the U.S. approval
lagged by 24 months. For all Wilcoxon signed rank comparisons the null and alternative
hypotheses were the following:
H01a: No difference exists in drug-lag between matched-pairs US-EU, US-LC,
EU-LC and US-24.
Ha1b: A difference exists in drug-lag between matched-pairs US-EU, US-LC,
EU-LC and US-24.
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RQ2: Are the covariates of year of U.S. approval, drug indication, orphan
designation, FDA review type, host country World Bank income category,
sponsor company market capitalization and country/region of company
headquarters associated with specific approval time/drug-lag categories
(expedient, average, delayed, or severely delayed) for individual products?
The dependent variable was the specific approval time/drug-lag category, and the
independent variable for each evaluation was one of the named covariates above. The
hypotheses for the year of U.S. approval (independent variable) and the approval
time/drug lag category (dependent variable) were:
H02a: Year of U.S. approval is not associated with specific approval time/drug
lag categories in all countries (expedient, average, delayed, severely delayed).
Ha2a: Year of U.S. approval is associated with specific approval time/drug lag
categories in all host countries (expedient, average, delayed, severely
delayed).
The null and alternative hypotheses for the covariate drug indication (independent
variable) and approval time/drug lag category (dependent variable) were:
H02b: Drug indication is not associated with specific approval time/drug lag
categories in all countries (expedient, average, delayed, severely delayed).
Ha2b: Drug indication is associated with specific approval time/drug lag
categories in all host countries (expedient, average, delayed, severely
delayed).
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The null and alternative hypotheses for the covariate orphan designation
(independent variable) and approval time/drug lag category (dependent variable) were:
H02c: Orphan designation is not associated with specific approval time/drug
lag categories in all countries (expedient, average, delayed, severely delayed).
Ha2c: Orphan designation is associated with specific approval time/drug lag
categories in all host countries (expedient, average, delayed, severely
delayed).
The null and alternative hypotheses for the covariate FDA review type
(independent variable) and approval time/drug lag category (dependent variable) were:
H02d: FDA review type is not associated with specific approval time/drug lag
categories in all countries (expedient, average, delayed, severely delayed).
Ha2d: FDA review type is associated with specific approval time/drug lag
categories in all host countries (expedient, average, delayed, severely
delayed).
The null and alternative hypotheses for the covariate host country World Bank
income classification (independent variable) and the approval time/drug lag category
(dependent variable) were:
H02e: Host country World Bank income classification is not associated with
specific approval time/drug lag categories in all countries (expedient, average,
delayed, severely delayed).
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Ha2e: Host country World Bank income classification is associated with
specific approval time/drug lag categories in all host countries (expedient,
average, delayed, severely delayed).
The null and alternative hypotheses for the covariate sponsor company market
capitalization (independent variable) and the approval time/drug lag category (dependent
variable) were:
H02f: Sponsor company market capitalization is not associated with specific
approval time/drug lag categories in all countries (expedient, average,
delayed, severely delayed).
Ha2f: Sponsor company market capitalization is associated with specific
approval time/drug lag categories in all host countries (expedient, average,
delayed, severely delayed).
The null and alternative hypotheses for the covariate sponsor company
headquarters location (independent variable) and the approval time/drug lag category
(dependent variable) were:
H02g: Sponsor company headquarters location is not associated with specific
approval time/drug lag categories in all countries (expedient, average,
delayed, severely delayed).
Ha2g: Sponsor company headquarters location is associated with specific
approval time/drug lag categories in all host countries (expedient, average,
delayed, severely delayed).
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Description of the sample population, including case inclusion and exclusion
criteria, the process and procedures for data collection, the time span of concentrated data
access, entry and cleaning, and the imputation method or assumptions for any missing
data is included in Section 3. A summary of the descriptive and inferential statistical
methods is included. I report descriptive statistics, the counts, the frequencies, ranges
(min-max), standard deviation, measures of central tendency (mean, median), and
percentages. I also report results from inferential statistical analyses.
Data Collection
U.S. Food and Drug Administration, European Medicines Agency, Clinical Trials
and National Ministry of Health Drug Approval Data
The FDA, EMA and many of the countries participating in international pivotal
trials post either a PDF, MS Excel spreadsheet or interactive database allowing queries
about local drug approval and date of the drug’s first approval on their public websites.
No sources accessed included any personally identifiable, confidential or otherwise
protected information. The FDA’s ADA reports are specific to year and include; drug
generic and brand name, date of approval, indication, sponsor name, whether orphan
designation was granted, and whether a priority or standard review was performed. The
ADAs are available in PDF format and required manual entry of the above variables into
a Microsoft Excel spreadsheet. Statistical and clinical sections from the FDA’s individual
DAPs, also in PDF format, were reviewed to ascertain details about each specific product
approved between 2006 and 2015. Statistical sections of DAPs included the statistical
reviewers’ determination of the specific clinical trials the FDA considered to be pivotal to
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the product’s approval. In some cases, the DAP included which specific countries pivotal
trials were performed in, but in approximately 80% of cases, the publicly available
databases Clinicaltrials.gov and the EudraCT on-line repository of clinical trials at
Eudract.europa.eu were searched for specific pivotal clinical trial site information. In
approximately 10% of cases, trial site data were not visible in these US or EU clinical
trial repositories, which required a medical literature search, completed through google
scholar. Ultimately, host country information was obtained for all pivotal trials completed
in the ten-year period.
Approval dates, generic and brand names and indications for all drugs in EU
countries were available from a comprehensive Microsoft excel spreadsheet downloaded
from the EMA website at https://www.ema.europa.eu/en/medicines. Searching for drug
approvals, indications and approval dates on ex-US country websites and databases was
done first on brand-name, and secondly on generic-name if the brand-name was not
recognized. The brand name of medications outside of the United States frequently
differs, but the generic name does not. Google-translate was used for all foreign language
websites except for Spanish, as the researcher is proficient in Spanish and English
languages. On-line Cyrillic and Turkish character translators were used for queries into
the ministry of health websites of Russia and Turkey.
Because the objective of this research is to describe global availability of drugs
approved by the FDA and to quantify and categorize any time-lag, relative to U.S. and
EU approvals, the gold-standard sources of approval and approval date data were national
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ministry of health websites or answers to direct queries from the researcher to the product
manufacturer.
Because there were gaps in availability of approvals and precise approval dates in
the countries referenced above, two additional approaches not specifically outlined in
Section 2 were taken to ascertain reliable drug approval and approval date data when
sponsor companies did not respond to queries, or their responses were not adequately
specific. The first approach was to complete internet searches of retail pharmacies for the
branded or generic name of the drug in countries without approval information posted on
ministry of health websites. The second approach was to request a free and time limited
subscription to the Springer Publications product ADIS-Insight product, which
aggregates data from approximately 200 different public websites to create profiles on
approved drug products. The latter approach permitted confirmation of approval, or not,
in each host country. Similar to Ministry of Health and all other internet-based sources of
data, the ADIS Insight product contained no confidential or protected health information.
Other sources of information for collection of covariate information were the World Bank
2014 spreadsheet for country incomes, which categorizes countries into 4 income
categories, corporate and/or product websites to ascertain the sponsor company’s
corporate headquarters location, and the databases of the New York Stock Exchange and
NASDAQ for historical market capitalization information. The two sources mentioned
above withstanding, all information from these data sources provided adequate and
complete information and is consistent with the prior data analysis plan proposed in
Section 2.
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Sampling and Time Frame
Permission to analyze the study data was granted by the Walden University IRB
on January 8, 2018, number 0534307. Following IRB approval, I downloaded the FDA
from 2006 to 2015, inclusive, and began manual entry into a master Microsoft excel
spreadsheet for all product approvals during the specified 2006-2015 time period on
January 21, 2019. Both generic and branded drug names were entered, as well as
approval date, indication, orphan status, review type and sponsor name from the FDA
reports. Following completion of manual entry of the above data, I downloaded the
EMA’s master approvals spreadsheet from 31 December, 2018. I searched the EMA’s
master spreadsheet by brand and generic names as well as indication and entered the
approval dates into the master spreadsheet. For those U.S. approved drugs not appearing
on the EMA’s approval list, I did an on-line search to determine whether any of the
missing drugs utilized a de-centralized review process in Europe versus the centralized
process represented in the EMA approval spreadsheet, approximately 15 examples of decentralized approval were found and those approval dates were entered into the master
spreadsheet as well.
I then reviewed the FDA’s DAP for each individual drug to determine whether
the product was truly an NME or a re-formulation or new combination of previously
approved products. I also noted whether the product was a therapeutic vs as imaging or
diagnostic agent. Finally, the statistical and clinical sections of each DAP were reviewed
to determine which trials were considered pivotal to approval. Protocol numbers and the
numbers of study participants were entered to assist in the next phase of the research,
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which was to consult the on-line databases clinicaltrials.gov and the EudraCT on-line
trial repository for host country information. All country information per-trial was
entered into the master Microsoft excel spreadsheet. I then entered data on covariates not
present in the FDA’s or EMA’s data sets. Each country’s World Bank income status was
manually entered from the World Bank’s 2014 global income spreadsheet, and the
market capitalization information on the date of the U.S. FDA’s approval was entered for
each company from NASDAQ or NYSE archival databases. Data entry was completed
on 13 April 2019, and consisted of approximately 9,000 manually entered fields.
Data Preparation
The data collected consisted largely of categorical data, with the exception of
dates of approval for each product in the United States, EU and the Last Country (LC)
approval date in which pivotal trials were conducted. Individual product approval dates in
the US, EU and LC are compared, and a difference between them calculated in months,
yielding the individual product drug-lag. Calendar approval dates from FDA (US), EMA
(EU) and individual country sources were entered into the master spreadsheet in a
dd/mm/yyyy format. Date differences in months were calculated in Microsoft Excel and
labeled as variables US-LC_lag(Mo); US-EU_lag(Mo) and EU-LC_lag(Mo),
respectively. In product cases where more than one host country had not approved a
product yet, i.e.; more than one country with the approval date of 4/1/2019, the host
country with the lowest World Bank income category was recorded in the WB income
category data field of the master spreadsheet to capture any potential associations
between drug lag and lower income countries.
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Values for drug-lag in months can be transformed into the four time-based
categories specified in section 2, but also can be grouped to create binary values
corresponding to US-LC, US-EU and EU-LC drug-lag ranges of 0-24 months and 24
months or greater, thus permitting the possibility of further post hoc inferential analyses
such as logistic regression.
Two of the covariates in research question 2, Orphan Status and FDA Review
Type also have binary values, i.e.; orphan vs. non-orphan, and priority vs. standard
reviews, respectively. The additional 5 covariates assessed for association with drug-lag
in research question 2, all have greater than 2 possible values. US Approval Year has ten
possible values corresponding to each of the ten years from 2006 through 2015. Broad
Drug Indication has 16 values; Sponsor Market Cap has 5 values; Host Country World
Bank Income has 4 possible values, and Company HQ has 4 values. Further detail on
potential groupings of covariates for research question 2 are included in the Data
Grouping section.
In the course of colleting the variables chosen for analysis and hypothesis testing,
I collected several additional relevant variables which are not part of hypothesis testing.
These variables are: overall number of countries participating in pivotal trials for the
sample, number of countries per-product in which pivotal trials were conducted and the
number of countries in which the product was not approved in greater than 1 country.
Those variables are reported descriptively in Table 9.
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Missing Data
Efforts were made to minimize missing data. The most significant challenge
encountered was the determination of drug approval dates for countries not posting
national formularies with drug approvals and approval dates on-line. Of the 82 countries
included in this sample which participated in pivotal clinical trials, the majority provide
public access to national formularies of approved drugs. Notable exceptions which do not
post formularies and approval dates on-line were; South Africa, Ukraine, China,
Thailand, Belarus, Mexico and the Philippines. The number of products each hosted
pivotal trials for are, in order or presentation above; 46, 33, 24, 25, 8, 51 and 17, totaling
204 or 8.1% missing cases of approval data for the pivotal trials leading to product
approvals between 2006 and 2015. The majority of pivotal trials each of the above
country participated in were large multi-national trials in which several of the above
countries were participants simultaneously. No cases existed where individual product
approval data and dates were unavailable for less than 70% of participating countries in
any specific product’s pivotal trials. However, given the proportion of missing data and
the fact that the missing data are not missing at random, i.e.; they were missing
consistently from specific participating countries, and the dependence of the calculation
of individual product drug-lag on the date of approval in the last host-country, further
efforts were made to determine approval status and date for all host countries (Little,
Jorgensen, Lang, & Moore, 2014). During the search efforts to fill in this specific gap, I
frequently encountered partial reports on the products of interest produced by the
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subscription-based product, ADIS-insight from Springer publications. The full reports
available only via subscription.
I contacted Springer publications on 04 April 2019 and described my objectives.
Springer personnel requested that I attend an on-line demonstration of their product to
determine whether it would be suitable for the research objectives, and the session
occurred on April 8, 2019. The demonstration clarified that the product would be useful
for providing missing approval and approval date information for products in the above
referenced countries. I was granted a free account for 2 weeks, which was the final data
collection effort made in this study. A profile within ADIS-insight was available for each
product I identified as having missing country approval and approval date data. Within
each product profile, a listing of all clinical trials, whether considered by FDA to be
pivotal or not, the participating countries of each, whether the product is approved, and
the date of approval for every country in which the product is licensed. Access to ADISinsight allowed all 204 cases of missing data for each country to be found. These data
were entered between April 9 and 13, 2019. The ADIS-insight database was not
originally specified as a secondary source in Section 2, as it was my belief that approval
and approval date information would be provided by national ministry of health websites
or other secondary and publicly-available sources.
Variables and Data Groupings
Table 8 below includes variable descriptions, types and field title for each
variable in the master data analysis spreadsheet. Research question 1 assesses the
proportion of products approved within 12 months or less of the FDA’s approval, when
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the FDA’s approval is the first approval in the world. Stated differently, research question
1 evaluates the proportion of products with a drug-lag of 12 months or less, relative to US
approval for products where the US approval was first in the world. 2 different approval
dates are used as benchmarks for calculation of the drug-lag. The first is the is the Last
Country (LC) approval date, which represents the most contemporary approval date for
the product in the country or countries where pivotal trials were conducted. The second
approval date upon which drug-lag is benchmarked is the EU approval date, which
represents centralized and decentralized approvals for each product in the 28 countries of
the European Union.
For all analyses, drug-lag in months is calculated by taking the difference of the
U.S. approval date and the most contemporary approval for that product in the LC;
abbreviated US-LC lag. Similarly, the US-EU drug-lag in months was calculated and
used as a reference population. An approval date of 4/1/2019 was entered for any country
in which the product was not yet approved at the time of this analysis. 12 cases exist
where all ex-US countries hosting pivotal trials were in the EU. In those cases, the LC
approval date is the same date as the EU approval date, making the US-LC drug-lag the
same as the US-EU drug-lag. Finally, for the EU-LC comparison, the drug lag would be 0
months for those 12 products, since the LC and EU approval dates are the same.
In section 2, I further specify the drug-lag into 3 additional time-based categories
beyond the 0-12 month (Expedient) category used in research question 1. The additional
3 drug-lag categories are; 13-24 months (Average), 25-60 months (Delayed) and greater
than 60 months (Severely Delayed). To enable additional post hoc inferential statistical
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analyses, drug-lag may be converted to a binary variable where 0 = a US-LC drug-lag
value of 24 months or less, and 1 = a US-LC drug lag value of 25 months or greater.
Research question 2 evaluates 7 covariates for association with the observed druglag category US-LC lag. 2 of the covariates analyzed in research question 2; Orphan
Status and FDA Review Type are nominal and binary, and the additional 5 covariates
included in research question 2 have 3 or greater categories within each. 2 of the
remaining 5 covariates are ordinal variables which can be ranked from low to high, i.e.;
Host Country World Bank Income Category, and Sponsor Market Capitalization. and
may be combined to allow valid statistical comparisons of categorical data based on low
observed frequencies in some categories with greater specificity. For example, the
covariate Broad Indication has 16 different categories within it. Grouping categories
within Broad Indication to a smaller number i.e.; Oncology, Anti-Infective and “Other”
may concentrate some less frequently approved product indications and permit inclusion
of Broad Indication in further post hoc inferential analyses. Therefore, while combining
categories sacrifices some descriptive specificity, it may permit further post hoc
inferential analyses to be performed.
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Table 8
Independent and Dependent Variables with Field Names
Variable Description
Approval year (2006-2015)

Field Title
Approval_Yr

Variable
Independent

Broad_Indication

Independent

Orphan indication

Orphan_Status

Independent

FDA review type

Review_Type

Independent

Last host country World Bank income category

LC_WB_Cat

Independent

Sponsor headquarters country

Sponsor_HQ

Independent

Sponsor_Mkt_Cap

Independent

Drug-lag: U.S. approval-EU approval (Mo)

US-EU_lag(Mo)

Index

Drug-lag: EU approval-LC (Mo) for Wilcoxon
Test
Drug-lag: Adjusted US-LC for Wilcoxon test

EU-LC_lag(Mo)

Index

US-LC_24

Simulation

Drugs approved in all countries within 12 mo.

US-LC_lag_Cat

RQ 1

Drug indication

Sponsor market capitalization at U.S. approval

Dependent
Drug-lag: U.S. approval-last host country
(months)

US-LC_lag(Mo)

RQ 2
Dependent
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Analysis of Results for the Study Sample
Sample Selection
I used IBM SPSS Version 25 statistical analysis package to conduct descriptive
statistical analyses of all demographic characteristics for all independent and dependent
variables. Counts, frequencies and percentages for each variable were calculated using
SPSS. Measures of central tendency and variability were calculated for each independent
and dependent variable as appropriate and those descriptive results are presented in
Tables 11 and 12.
The sample selection details included in Figure 4 and Table 8 were handtabulated. The counts of censored cases by reason from the total sample are included in
Figure 4 and Table 8 and I have included the narrative justification for censoring each
type of case in this section. Because the primary purpose of this study is to investigate the
global availability of products in countries which participated in pivotal clinical trials,
and to measure the time to that availability, the primary filter on the total NME approvals
between 2006 and 2015 is removing cases where the U.S. FDA’s approval was not the
first in the world. Concentrating on products with the distinction of FDA’s first in world
approval allows an objective benchmark with which to measure drug-lag, due to the
transparency and detail of records that the FDA makes publicly available.
The total count of NMEs approved by the FDA between Jan 1, 2006 and
December 31, was 293. 64 cases (22%) of the total approvals were removed due to
FDA’s approval not being first in world, which represents the largest category of
censored cases. The second most frequent reason for censoring cases was that pivotal
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trials did not include ex-US patients. 37 products (13%) did not include ex-US patients in
their pivotal trials. Even if such cases were first in world approvals, the exclusivity of US
patients in pivotal trials changes the ethical landscape, as the risks and burdens of clinical
research were borne by the U.S. population exclusively, versus shared between the US
and other countries. Another ethical consideration in cases where pivotal trials were
conducted in US patients exclusively is that, so long as the effective drug is available to
those populations who were research subjects, the principle of justice is upheld.
The third most frequent reason for censoring cases was if the marketing
application was withdrawn in the EU and/or all ex-US markets, which occurred 23 times
(7%) of cases. Censoring these cases is justified, as including them would raise the
possibility that the drug-lag value would be falsely inflated due to the sponsor’s
abandonment of plans to market in all countries where the product performed pivotal
trials. It is assumed that by rejection or withdrawal of ex-US marketing applications,
sponsors will never seek approval in these ex-US countries, thereby theoretically inflating
the drug-lag value. Fourth, NME products which were not therapeutic, n=10 (3%) were
censored from the sample, as there is an assumed diminished drive to market in nonpremium paying countries and the ethical force driving access to a non-therapeutic agent
vs a new therapeutic agent is assumed to be weaker. Finally, 2 cases were found (1%)
where the products which appeared in the FDA’s annual NME approval report which
were new formulations of already approved drugs or a new combination which did not
contain any new agent. The final total sample for this study of the NMEs approved
between 2006 and 2015, considering all adjustments is 157, or 54% of the 293 (291)
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NME products approved by the FDA in that ten-year period. My 54% ratio of selected
cases to total NMEs approved within the 2006-2015 period is similar to the ratio of US
first in world approvals reported by Larochelle, et al in their review of FDA NME
approvals between 2000-2010 for a different objective. Their sample had 61% (172 of
282) of the total FDA NME approvals between 2001 and 2010 were U.S. first in world
approvals, a difference of less than 10% from my 2006-2015 sample` (Larochelle,
Downing, Ross, & David, 2017).
Table 9
Final Sample Selection Details
Variable
Total FDA Approvals of New Molecular Entities (20062015)
Adjustments

Frequency
N=293

Percent
N=100

2

1

Not a therapeutic agent

10

3

Pivotal trials did not include Ex-U.S. patients

37

13

FDA approval was not first in world for product

64

22

Marketing application withdrawn or rejected

23

7

157

54

Not first approval for that NME

Total
Note. n=157.

Additional demographic data not included in hypothesis testing, but relevant for
understanding the overall context of the sample are included below in Table 10.
Importantly, 71 of the 157, or 45% of the products in the sample remain unapproved as of
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April 1, 2019 in more than one country which hosted pivotal trials between 2006 and
2015. 82 unique countries in the sample hosted at least one pivotal trial, and the
development of the 157 products included in the sample were sponsored by,
coincidentally, 82 unique companies. 26 of the 82 sponsor companies were acquired by
or merged with another company at the time of U.S. marketing application filing or prior
to FDA product approval. Because the sponsor company market capitalization covariate
was measured on the date of the U.S. product approval, mergers and acquisitions may
affect the interpretation of the market capitalization covariate, as post-merger/acquisition
market capitalizations reflect those of the acquiring company, i.e.; a larger market
capitalization than the acquired company. The descriptive statistics of host countries perproduct demonstrate globalization in drug development between 2006-2015 with
minimum-maximum values of 1-39 ex-US countries hosting pivotal trials, with a mean
number of 16 host-countries per product.
Table 10
Relevant Additional Data
Variable

N

Min

Unique sponsor companies in sample

82

Sponsor company merger/acquisition

26

Unique host countries in sample

82

Product remains unapproved in 1 > country

71

Host countries per product in sample

157

1

Max

39

Mean

16

Std. deviation

9.71
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Descriptive Statistics of Variables Used in Hypothesis Testing
Drug-lag is the dependent variable of interest for research questions 1 and 2, and
therefore descriptive statistics will first be reported for the 3 regional assessments of
drug-lag; US-EU lag, US-Last Country (LC) lag, and EU-Last Country (LC) lag.
Descriptive Statistics and measures of central tendency are reported in Table 11. The
number of valid cases for each regional drug-lag calculation is 157. The largest mean and
median values for drug-lag occur in the U.S.-Last Country assessment at 66 and 63
months, respectively. The EU-Last country assessment has mean and median values of
53.1 and 50 months, respectively, followed by the shorter mean and median drug-lag
observed in the U.S.-EU assessment of 12.6 and 7 months, respectively. U.S.-EU and
EU-LC assessments both include minimum values of zero, as in the former case, products
in the sample were approved by the FDA and the EMA within 30 days of each other. In
the case of the EU-LC assessment, the minimum zero value corresponds to
products/cases where host countries outside the European Union did not participate in
pivotal trials, therefore making the drug-lag zero months for those cases.
Table 11
Descriptive Statistics and Measures of Central Tendency Drug Lag in Months
Variable
(valid)
US-EU Lag (Mo)
US-LC Lag (Mo)
EU-LC Lag (Mo)
Note. (n = 157).

N

Percent
Minimum Maximum Mean Median Std.
deviation
(N =
100)
157
100
0
136
12.6
7
17.98
157
100
1
158
66.0
63
42.02
157
100
0
144
53.1
50
40.99
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Descriptive statistics of the additional 7 independent variables included in
research question 2 are included in Table 11. I report valid cases, frequencies and percent
for categorical variables in Table 12. For the variable Year of FDA Approval, years 6-10
(2011-2015) have nearly two-thirds, or 63.7% of the FDA approvals for this sample in
the decade studied. The single year with the largest number of approvals in this sample
was 2015, with 24 approvals. The variable Broad Indication, the largest indication
approved during the decade in this sample was Oncology with 54 products approved, or
33.1% of the total products approved. Anti-Infective products, with 29 approvals,
constitutes 18.5% of the approvals in the period and was the only other indication with
greater than 10% of the approvals in this sample in the period. The Last Host Country
World Bank Income Category had High Income Countries as the most frequent, at 65 or
41.4%. Upper Middle Income and Lower Middle-Income Countries were similar with
29.9% and 28.7% of approvals, respectively. While two World Bank Low Income
Countries participated in the pivotal trials included in the sample, neither Tanzania nor
Uganda were a Last-Country, and therefore the Low-Income category appears as zero in
this analysis.
The Product Sponsor Market Capitalization variable has 5 categories, and is
dominated by large cap companies, with 107, or 68.2% of the approvals in the sample
being achieved by large cap companies. Large-cap companies were defined previously as
having a market capitalization of over $10 billion dollars. Also as previously mentioned,
due to corporate acquisitions during the sample period, of the 157 product approvals in
the sample, 82 individual companies were represented. Proportionally, Mid-Cap, Small-
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Cap, Micro-Cap and Private companies have similar numbers of approvals in the sample.
Similarly, the majority of pivotal trial sponsors were companies with headquarters in the
United States, 61.8% and the EU 33.1%. Japanese and one Canadian company received
product approvals in the sample period, respectively. For FDA Review Type, Priority
Reviews (FDA action within 6 months) were more frequently granted at 53.7% than
Standard Reviews (FDA action within 10 months), which were granted 42.7% of the
time. Finally, Orphan designation, i.e. the product’s target indication is relatively rare,
afflicting 200,000 or fewer patients in the United States, was granted in 37.6% of the
product approvals in this sample, versus non-Orphan designation, which is standard for
non-rare diseases and occurred in 62.4% of the products approved in this sample.
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Table 12
Descriptive Statistics for Categorical Variables
Variable
(Valid)
Year of FDA Approval
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
Total
Broad Drug Indication
Anti-Infective
Allergy/Immunology
Anesthesia/Analgesia
Cardiovascular
Dermatology
Endocrinology
Genito-Urinary
Hematology
Musculoskeletal
Neurology
Oncology
Ophthalmology
Psychiatry
Pulmonary
Rare Diseases
Total
Last Host Country Income Category
World Bank High Income (HI)
World Bank Upper Middle Income (UMI)
World Bank Lower Middle Income (LMI)
World Bank Low Income (LI)
Total
Product Sponsor Company Market Capitalization
Large Cap
Medium (Mid) Cap
Small Cap
Micro Cap
Private Company
Total
Trial Sponsor World HQ Location
United States
EU
Canada
Japan
Total
FDA Review Type
Priority Review
Standard Review
Total
Orphan Designation
Orphan
Non-Orphan
Total

Note. (N = 157).

Frequency
(N = 157)

Percent
(N = 100)
14
11
9
12
11
15
22
16
23
24
157

8.9
7
5.7
7.6
7
9.6
14
10.2
14.6
15.3
100

29
6
1
9
1
13
2
5
1
8
52
4
7
2
10
157

18.5
3.8
0.6
5.7
0.6
8.3
1.3
3.2
0.6
5.1
33.1
2.5
4.5
1.3
6.4
100

65
47
45
0
157

41.4
29.9
28.7
0
100

107
11
14
14
11
157

68.2
7
8.9
8.9
7
100

97
52
1
7
157

61.8
33.1
0.6
4.5
100

90
67
157

57.3
42.7
100

59
98
157

37.6
62.4
100
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Evaluation of Statistical Assumptions
The hypothesis testing for Research question 1 relies upon arithmetic proportions
and therefore requires no additional preparation or testing for normality or linearity as
would be necessary when choosing parametric or non-parametric inferential analyses.
The second level of testing for research question 1 is a statistical analysis of the paired
observations in the sample using the Wilcoxon Signed Rank Test of Paired Samples to
determine whether observed differences between the U.S.-EU, the U.S.-LC and the EULC values for drug-lag have more than a zero difference from each other. In section 2, a
fourth, simulated sample was proposed, which included a mean and median value of 12
months for drug-lag. This sample was intended to simulate a mean US drug-lag value of
12 months, for comparison to the U.S.-EU, U.S.-LC, EU-LC drug lag values. In Table
10, however, the descriptive results of the US-EU drug-lag show a mean drug lag of 12.6
months, and therefore, the prospectively defined simulation sample of 12 months was
abandoned, and the simulated sample was changed to a simulated sample with a mean
drug-lag value of 24 months. The simulated sample US-24 was compared to U.S.-EU,
U.S.-LC and EU-LC samples with the Wilcoxon test and the results are included in Table
15.
Determination of normality, i.e.; whether the data from my sample are normally
distributed, determines which inferential tests are appropriate for analysis. Assumption of
normality can be achieved by generation of a histogram to see, roughly, whether the
shape of the histogram approximates a normal bell-curve, and if so, the data are likely to
be normally distributed (Glantz, 2012). Visualizing the histograms of the U.S.-EU, U.S.-
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LC, EU-LC, and US-24 data, none appear to be normally distributed. More specific than
a visual approximation, are the tests of normal distribution present within SPSS version
25. I chose the Kolmogorov-Smirnov (K-S) and the Shapiro-Wilk’s tests to assess the
normality of each of the independent and dependent variables in my sample. If the results
conflicted between the 2 tests for normality, the Shapiro-Wilk’s result was used. The
results of the normality tests are presented in Table 13. If the results of the tests for
normality are statistically significant at the level of p < .05, then this causes a rejection of
the null hypothesis which states that the data are normally distributed (Glantz, 2012).
Therefore, because all Shapiro-Wilk’s test results are statistically significant, the
assumption is that all 4 groups tested are not normally distributed.
Table 13
Tests for Normality of Data
Variable
US-EU Lag (Mo)
US-LC Lag (Mo)
EU-LC Lag (Mo)
US-24 Lag (Mo)
Note. * p < .05

K-S Result Shapiro-Wilk’s result
.000*
.000*
.076
.000*
.001*
.000*
.000*
.000*

Research question 2 is an assessment of a series of associations between ordinal,
time-based categories of drug-lag and other nominal variables obtained from the FDA,
the EU, the World Bank, NASDAQ and NYSE and other sources potentially associated
with the time to approval of products in countries which performed pivotal trials. No
specific preparation of the nominal variables analyzed via chi-square analyses is
necessary to determine whether these variables are associated with time-based categories
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of drug-lag. For nominal variables with significant numbers of categories within them,
such as Broad Indication, grouping of less frequent indications together will allow, on a
post hoc basis consolidation of cases into a smaller number of cells in the contingency
table. Such groupings, while decreasing specificity of results, may yield identification of
significant positive or negative associations of independent variables with the dependent
variable. Similarly, a post hoc consolidation of the four categories of the dependent
variable into two categories; Average (0-24 month lag) and Delayed (25 months or
greater) may yield associations with covariates that the n=157 sample size did not permit
with the more specific original drug lag categories of the dependent variable.
Inferential Analysis
Research Question 1: Proportions Analysis and Wilcoxon Signed Rank Tests
RQ1a: Of the NME’s first approved by the US FDA between 2006 and 2015
which included ex-US patients in pivotal trials, what proportion of drugs achieved
expedient approval/drug-lag of 0-12 months in all participating countries?
H01a: Fewer than 66% of all NMEs approved by the FDA will be approved in
all host countries within 12 months.
Ha1a: 66% or greater of all NMEs approved by the FDA will be approved in
all host countries within 12 months.
Of the 157 FDA approvals granted in the sample period, i.e.; between January 1,
2006 and December 31, 2015, a total of 15, or 9.6% of products were approved in the last
participating country within 12 months of the US FDA’s approval. This proportion is less
than the 66% stipulated in the null hypothesis, and therefore, for research question 1, the
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null hypothesis is accepted. Table 14 presents more detail on the drug-lag for the 157
product approvals in the U.S.-Last Country sample, which is the primary population for
Research Question 1. Table 14 also presents the proportional drug-lag data from the USEU sample and the EU-Last Country sample for comparison. Testing the same hypothesis
with the US-EU and the EU-LC samples leads to different results than observed with the
U.S.-LC sample. At 12 months post FDA approval, 72% of the drugs approved in the US
are also approved in the EU. This observation would cause a rejection of null hypothesis
for the US-EU sample, as the 12-month threshold is 66%. Conversely, for the EU-LC
sample, while a greater proportion, 22.9% of products were approved within 12 months,
the null hypothesis would not be rejected for this sample, as the threshold for rejection is
66%. The null hypothesis of the Wilcoxon Signed Rank Test analyzes paired related
samples, and assumes that the samples have a difference of zero. Therefore, a comparison
of each drug-lag sample paired against another, i.e.; U.S.-EU_lag versus U.S.-LC_lag
will assess if there is a difference in drug-lag between the paired samples.
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Table 14
Drug-Lag for the US-Last Country; US-EU and EU-Last Country Samples in Months
Sample/Drug-lag category

Number of approvals

Percent

U.S.-last country sample
0-12 Months (expedient)
13-24 Months (average)
25-60 Months (delayed)
Greater than 60 months (severely delayed)
Total

15
18
45
79
157

9.6
11.5
28.7
50.3
100

U.S.-EU sample
0-12 Months (expedient)
13-24 Months (average)
25-60 Months (delayed)
Greater than 60 Months (severely delayed)
Total

113
26
13
5
157

72
16.8
8.3
3.2
100

36
11
46
64
157

22.9
7
29.3
40.8
100

EU-last country sample
0-12 Months (expedient)
13-24 Months (average)
25-60 Months (delayed)
Greater than 60 months (severely delayed)
Total
Note. (N = 157).
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Wilcoxon Signed Rank Test of Paired Samples.
The three drug-lag samples; US-EU-Lag, US-LC-Lag, EU-LC-Lag and a
simulated sample, US-24_Sim were tested and assessed for differences from each other
by the Wilcoxon Signed Rank Test. The results are reported in Table 15 below. All
samples have p-values less than 0.01 and thus, the null hypothesis of the drug-lag in
months being the same for each paired sample is rejected, both for the 3 pairs tested with
the observed real data, and the 3 pairs tested in the US-24 simulation.
Table 15
Wilcoxon Signed Rank Test of Observed and Simulated Paired Samples
Paired Samples
N = 157
US-EU and US-LC
US-EU and EU-LC
US-LC and EU-LC
US-EU and US-24 simulation
US-LC and US-24 simulation
EU-LC and US-24 simulation
Note. *p < .05

Z Statistic

P Value

-10.353
-8.526
-10.769

< .001*
< .001*
< .001*

-8.529
-9.371
-7.399

< .001*
< .001*
< .001*

Research Question 2: Chi-Square Analyses
Seven covariates, approval year, broad drug indication, last host country World
Bank income category, product sponsor market capitalization, sponsor headquarters
location, FDA review type, and orphan designation were assessed for association with the
dependent variable, drug-lag between the U.S. approval and drug approval in the last
country. If a drug remained unapproved in a pivotal trial country as of 01 April 2019, that
date was entered as the cutoff. 71 products were identified where the drug remained
unapproved in more than one pivotal trial country at the 01 April 2019 cutoff date. In
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those cases, the World Bank Income Category for the lowest unapproved country was
recorded. Prospectively, magnitude of drug-lag from FDA approval was defined into four
categories: expedient (0-12 months of lag), average (13-24 months of lag), delayed (2560 months of lag), and severely delayed (greater than 60 months of lag). Chi-square
inferential analysis was performed to identify association and its effect size, if any, of the
identified relationship.
For covariate 1 in RQ2, FDA approval year, the null hypothesis was the
following:
H02a: Year of FDA approval is not associated with specific approval time/drug
lag categories in all countries (expedient, average, delayed, severely delayed).
Detailed chi-square results for each independent variable comparison are presented in
Table 15. Results of the prospective chi-square analysis of association of FDA approval
year to US-LC drug-lag was statistically significant, p < .001 with a moderate to large
Cramer’s V effect size of .461 (Pallant, 2005). This indicates a rejection of the null
hypothesis of no association between FDA approval year and US-LC drug lag, and
acceptance of the alternative hypothesis that there is an association between FDA
approval year and US-LC drug-lag. This result was tested further in a post hoc analysis.
For covariate 2 in RQ2, broad drug indication, the null hypothesis was the
following:
H02b: Broad drug indication is not associated with specific approval time/drug lag
categories in all countries (expedient, average, delayed, severely delayed).
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Results of the prospective chi-square analysis for association between broad drug
indication and US-LC drug-lag were not significant, p = .510, leading to the acceptance
of the null hypothesis that broad drug indication is not associated with US-LC drug lag.
For covariate 3 in RQ2, orphan status, the null hypothesis was the following:
H02c: Orphan status is not associated with specific approval time/drug lag
categories in all countries (expedient, average, delayed, severely delayed).
Results of the prospective chi-square analysis for association between orphan status and
US-LC drug-lag were not significant, p = .144, leading to the acceptance of the null
hypothesis that orphan status is not associated with US-LC drug lag.
For covariate 4 in RQ2, FDA review type, the null hypothesis was the following:
H02d: FDA review type is not associated with specific approval time/drug lag
categories in all countries (expedient, average, delayed, severely delayed).
Results of the prospective chi-square analysis for association between FDA review type
and US-LC drug-lag were not significant, p = .119, leading to the acceptance of the null
hypothesis that FDA review type is not associated with US-LC drug lag.
For covariate 5 in RQ2, last host country World Bank income category, the null
hypothesis was the following:
H02e: Last host country World Bank income category is not associated with
specific approval time/drug lag categories in all countries (expedient, average,
delayed, severely delayed).
Results of the prospective chi-square analysis for association between last host country
World Bank income category and US-LC drug lag were significant at the p < .001 level
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and a moderate to large Cramer’s V effect size of .427, which is moderate to large
(Pallant, 2005). This level of association between last host country World Bank income
category and US-LC drug lag, causes a rejection of the null hypothesis stating no
association between the 2 variables, and an acceptance of the alternative hypothesis
stating that an association exists.
For covariate 6 in RQ2, sponsor company market capitalization, the null
hypothesis was the following:
H02f: Sponsor company market capitalization is not associated with specific
approval time/drug lag categories in all countries (expedient, average, delayed,
severely delayed).
Results of the prospective chi-square analysis for association between sponsor company
market capitalization and US-LC drug-lag were not significant, p = .690, leading to the
acceptance of the null hypothesis that sponsor company market capitalization is not
associated with US-LC drug lag.
For covariate 7 in RQ2, sponsor company headquarters location, the null
hypothesis is the following:
H02g: Sponsor company headquarters location is not associated with specific
approval time/drug lag categories in all countries (expedient, average, delayed,
severely delayed).
Results of the prospective chi-square analysis for association between sponsor company
headquarters location and US-LC drug-lag were not significant, p = .872, leading to the

130
acceptance of the null hypothesis that sponsor company headquarters location is not
associated with US-LC drug lag.
Table 16
Chi-Square Results of Independent Variables for Research Question 2
Independent variable
FDA approval year
Broad drug indication
Orphan status
FDA review type
Last host country World Bank
income
Sponsor company market cap
Sponsor company HQ location

157
157
157
157
157

100.07
43.02
5.41
5.84
57.23

27
45
3
3
6

< .001*
.510
.144
.119
< .001*

Cramer’s V
(effect size)
.461 (Mod-Lg)
NA
NA
NA
.427 (Mod-Lg)

157
157

8.34
3.55

12
9

.690
.872

NA
NA

N

Chi Square

p value

df

Note. *p < .05
Post Hoc Analyses
I conducted several post hoc chi square tests to confirm the findings of association
between the 2 independent variables found to have associations, and the dependent
variable of drug-lag time category. The Year of FDA Approval was tested again, in two
ways, to account for the fact that the approval cutoff date of 01 April 2019 can truncate
the outer boundary of the drug lag for the years 2014 and 2015. Specifically, the April 1,
2019 cutoff date, the maximum values of drug-lag for 2014 and 2015 are 40 months and
56 months, respectively, which causes a truncation that may affect categorization into
US-LC drug lag categories 3 (26-50 Months) or 4 (50 months or greater). Furthermore, if
the 10-year FDA Approval Years are divided into 2, 5-year periods, i.e.; 2006-2010 and
2011-2015, the number of samples in each period is nearly twice the number in the latter,
2011-2015 period than the 2006-2010 with 100 approvals, and 57 approvals, respectively.
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The 2 different post hoc analyses completed to confirm an association between
year of FDA approval and US-LC drug lag were: 1) a 4x2table with transformation of the
year of FDA approval into 2, 5-year categories corresponding to 2006-2010 and 20112015 as the independent variable with no change to the existing 4 categories of US-LC
drug lag and 2) a transformation of the dependent variable into 2 categories; one being 012 month drug-lag and the other being greater than 12 months of drug lag, which creates
a 2x2 table for cross-tabulation and chi square testing. Results of post hoc analysis 1
demonstrate no change in the significance of the association, with a p value < .001,
however the Cramer’s V effect size was decreased slightly .367, indicating a moderate
effect size (Pallant, 2005). Results of post hoc analysis 2 for FDA Approval Year
demonstrate a change in the level of significance for association to non-significant, with a
p value = .801, indicating an acceptance of the null hypothesis, stating no relationship
between FDA Approval Year and US-LC drug lag.
I performed a similar post hoc confirmation of association between Last Host
Country Income level and US-LC drug lag via 2 comparisons, similar to those post hoc
analyses completed for the FDA Approval Year. I first divided the Last Country World
Bank income levels into 2 categories; high, and low. High consists of the high income
and upper-middle income countries, and low consists of the lower-middle income
countries, recalling that there were no World Bank low-income countries included in the
sample. The second post hoc analysis was completed by making the same change to the 4
U.S.-LC drug lag categories, reducing them to 2 and generating a 2x2 table with 0-12
months as one category, and 13 months and greater, the other. Results of both chi square

132
comparisons demonstrate p values < .05, which further confirms an association and with
Cramer’s V and Phi effect sizes of .339 and .206, respectively. The former corresponds to
a moderate effect size, with the latter corresponding to a small-medium effect size
(Pallant, 2005). Detailed results of all chi square post hoc analyses are included in Table
17.
Table 17
Post Hoc Confirmation Analyses of FDA Approval Year and World Bank Income
Category
Independent variable
FDA approval year 2x4 table
FDA approval year 2x2 table
Last host country World Bank
income 2x4 table
Last host country World Bank
income 2x2 Table
Note. * p < .05

N

Chi Square

p value

df

157
157
157

22.14
.063
18.00

3
1
3

157

6.66

1

Cramer’s V /Phi
(effect size)
< .001*
.367 Moderate
.801
NA
< .001*
.339 Moderate
< .05*

.20 Small

Summary of Analyses of Research Questions and Transition
The main objective of this study was to quantitatively measure the time lag
between U.S. FDA approval and the approval of new drugs in all countries that
participated in trials deemed by the FDA to have been pivotal to each drug’s approval.
Measurement of drug-lag was the main objective of this study, and was completed by
using secondary data from the U.S. FDA, the EMA, publicly available national formulary
data from participating countries ministry of health websites, and by one subscriptionbased information product, the ADIS insight report, provided free of charge from
Springer publications. By selecting those new drugs approved between Jan 1, 2006 and
December 31, 2015, where FDA’s was the first approval in the world, and measuring the
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time-lag in months between FDA’s approval and approval in the last host country for
each product, I was able to complete the calculation of drug-lag between the United
States and the last country in which approval was granted, if approval was granted for the
product. In the case that an approval was not granted, the cutoff date of April, 1 2019 was
imputed. Because of its similar role as a centralized regulatory agency, the European
Medicine’s Agency’s approval date for each drug was recorded, and U.S.-EU drug-lag
was calculated and used as a reference population from which additional comparisons
could be drawn.
In this 10-year sample, I counted the proportion of drugs approved within 12
months of the FDA’s approval, in the last host country for each product’s pivotal trial.
The null hypothesis was that fewer than 66% of FDA approved drugs would be approved
in the last country within 12 months of FDA approval. The results demonstrate that 9.6%
of FDA’s first in world approvals between 2006 and 2015 were approved in all host
countries within 12 months. This observation caused an acceptance of the null
hypothesis. Further descriptive observations of the U.S.-last country drug-lag
demonstrated that slightly fewer than 50% of products were approved in all host
countries within 60 months of the U.S. approval and slightly greater than 50% of drugs
took greater than 60 months to be approved, if they were approved in all host countries,
with a mean drug-lag of 66 months. The U.S.-EU drug lag was calculated and the mean
drug lag was 12.6 months. Finally, the EU-Last country drug lag was calculated and the
mean drug lag was 53.1 months. Wilcoxon Summed Rank Tests were then performed on
each paired sample; the U.S.-last country drug lag versus U.S.-EU drug-lag, U.S.-LC
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drug lag versus EU-Last country drug lag and EU drug-lag versus EU-LC drug-lag. Each
pair of samples were found to be different from each other at the p < .001 level. Each pair
was then tested against a simulated drug lag value of 24 months with the same Wilcoxon
test. Each pair in the simulated comparison was also found to be statistically significantly
different from each other at the p < .001 level.
Research question 2 assessed the association between 7 independent covariates
and the dependent variable of US-LC drug-lag, divided into four, time-based categories;
0-12 months, 13-24 months, 25-60 months and greater than 60 months. The null
hypothesis for all independent covariates was that there was no association between the
covariates and the dependent variable, U.S.-LC drug lag. The 7 independent covariates;
FDA approval year, drug indication, orphan status, FDA review type, World Bank
income category, sponsor market capitalization and sponsor headquarters were all tested
with chi square analysis for association with U.S.-LC drug-lag. Two independent
covariates; FDA approval year and last country World Bank income category
demonstrated associations with the dependent variable, both at the p < .001 level, with
moderate to large Cramer’s V effect sizes of .461 and .427, respectively. Therefore, a
rejection of the null hypothesis of no association, and acceptance of the alternative
hypothesis of an association between the 2 covariates and U.S.-LC drug-lag was made.
Post hoc confirmation testing of both covariates was done by combining
categories and reducing the numbers of cells in the chi square cross tabulations for both
independent and dependent variables, first to 4x2 tables and then further to 2x2 tables.
FDA approval year remained associated when the 10-year period was reduced to 2 5-year

135
periods, p < .001, with a moderate Cramer’s V effect size of .367. When the dependent
variable was reduced to 2 categories, 0-12 month and 13-months and greater US-LC drug
lag, the 2x2 cross tabulation and chi square testing demonstrated a non-significant result,
p = .800. Similar post hoc confirmatory testing of the last country World Bank income
category resulted in the following stages; reduction of the LC World Bank income
categories to 2, High and Low, while maintaining the 4 U.S.-LC drug lag categories,
producing a 4x2 cross tabulation table for chi square analysis. The results were
significant for an association p < .001 with a moderate Cramer’s V effect size of .337.
Further reducing the U.S.-LC drug lag categories, to 2, as with FDA approval year and
producing a 2x2 table for cross tabulation and chi square analysis gave results of p < .05
for association and a low phi effect size of .200.
Section 4 includes the interpretation of the results summarized in this section. I
also compare the study results and interpretations to regulatory and human rights policy,
as well as to the literature base. Limitations of the study, which portions of the findings
are most generalizable and which may require additional investigation are presented.
Finally, implications for positive social change are presented in conclusion.
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Section 4: Applications to Professional Practice and Implications for Social Change
In parallel with the globalization of clinical trials since the 1990s, questions of
equal and timely access to new drugs for all research participants and their communities
remain unanswered (U.S. FDA, 2017a; Kass et al., 2014). Sponsoring companies are not
universally required to make products available, nor to report when their products
become available in all countries that hosted their pivotal trials, though efforts have been
made to construct an objective ethical scorecard for companies’ performance (Miller et
al., 2017). Calculation and examination of the lag-time to availability, or drug lag, in the
last host country is an important potential measure of corporate social responsibility has
not been completed on an annual or decade-to-decade basis in parallel with the increased
globalization of clinical trials, and thus, there is a significant gap in the literature on the
time to global availability of new products (U.S. FDA, 2017a; Tufts Center for the Study
of Drug Development, 2009).
The primary purpose of this study was to measure, quantitatively, the lag-time
between NMEs approved first in the United States between 2006-2015, and their
approvals in the last country that participated in clinical trials considered as pivotal to
each drug’s FDA approval. The secondary objective was to identify factors associated
with the magnitude of the lag time between U.S. and last host country approval of
products. The secondary research question in my study examined seven independent
covariates for a possible association with the duration of drug-lag during the 10-year
period that I examined in my study.
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The primary data for analysis were collected from the websites of the FDA, the
EMA, host country ministries of health, Clinicaltrials.gov, the EU Clinical Trials
Registry, the World Bank, and NASDAQ and New York Stock Exchange databases,
which are publicly available on-line sources. At the conclusion of data collection from
publicly available sources, I noted that several countries consistently had gaps in access
to their approval and date of approval data. To address the missing data, I contacted
Springer publications, the producer of ADIS insight, a product that provides reports on
every U.S. approved drug and data on each product’s approval globally. I requested a free
trial of access to this product, which was granted, and I was able to complete the
collection of missing data from countries not posting approved drug formularies on-line
and in English.
I explored two research questions. RQ1 was the primary objective of the study
and assessed what proportion of drugs approved in the United States between 2006 and
2015 for which the FDA approval was the first in the world were approved in all
countries that hosted pivotal clinical trials within 12 months of the FDA’s approval.
Specifically, the null hypothesis for RQ1 was that fewer than 66% of products first
approved by the FDA between 2006-2015 would be approved in all countries that hosted
pivotal trials within 12 months of FDA approval. The U.S.-last country drug lag value in
months was the value that tested the hypotheses in RQ1. Further descriptive
categorization of the U.S.-last country drug lag was done based on the length or
magnitude of the drug lag and placed into four categories: expedient (0-12 months),
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average (13-24 months), delayed (25-60 months), and extremely delayed (60 months or
greater).
Following the hypothesis testing and drug lag categorization in RQ1, I calculated
specific drug-lag was calculated between the United States and EU to provide a reference
population, as well as to assess and compare the magnitude of the EU-last country drug
lag to the U.S.-last country values. Each pair was then tested by a Wilcoxon summed
rank test for paired data to determine whether drug lag values were significantly different
from each other. A U.S. drug lag of 24 months was also added to the Wilcoxon summed
rank test to simulate a value for the 64 cases not included in this analysis, because the
FDA approval was not the first in the world. The 24-month lag simulation was done to
provide a further benchmark by which to assess the magnitude of the last country drug
lag across a spectrum of possibilities beyond those where the FDA provides the first in
world approval for a product.
Of the 293 NMEs approved by the FDA between 2006 and 2015, 157 (54%) of
NMEs met the main criteria for inclusion in my sample, which were: that the NME was
therapeutic versus a diagnostic agent, that the FDA approval was the first in the world,
and that the NME’s development included countries outside the United States. The
results of the analysis of RQ1 demonstrate that the median drug lag between the U.S.
approval and the last host country approval was 63 months. Specifically, 15 of 157
(9.6%) of products were approved in all host countries within 12 months of FDA
approval. This proportion was below the 66% approval threshold prospectively identified
in the null hypothesis of research RQ1, and thus, the null hypothesis was accepted.
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Further, the proportions of drug approvals in the last host countries within 13-24 months,
25-60 months, and greater than 60 months were 11.5%, 28.7% and 50.3%, respectively.
By comparison, the drug lag between the United States and EU demonstrates that
median U.S.-EU drug lag was 7 months. A similar examination of the U.S.-EU drug lag
categories demonstrates that 113 of 157 (72%) of products were approved in the EU
within 12 months of U.S. approval. Further, 16.8% were approved between 13-24
months, 8.3% were approved between 25-60 months, and 3.2% in 60 months or greater.
Wilcoxon summed rank testing of the U.S.-EU drug lag compared to the U.S.-last
country drug lag was found to be significantly different, p < .001. Similarly, while the
EU-last country median drug lag at 50 months was shorter than U.S.-LC lag, when tested
by the Wilcoxon summed ranks test against the U.S.-EU lag, and the U.S.-LC lags, the
differences were both significant at the p < .001 level. I tested a simulated median U.S.
drug-lag of 24 months against the U.S.-EU lag, the U.S.-LC lag and the EU-LC lag and
all were found to be statistically significantly different at the p < .001 level as well.
Finally, I also noted that of the 157 drugs in the sample, 71 products (45%) remain
unapproved as of the April 1, 2019, cutoff date in at least one country that hosted pivotal
clinical trials between 2006 and 2015.
With RQ2 I evaluated through chi-square testing whether any association existed
between the covariates of year of FDA approval, drug indication, orphan status, FDA
review type, World Bank income category of last host country, and the sponsor
characteristics of market capitalization and country of sponsor headquarters. These
independent variables were each tested against the dependent variable, drug lag, for
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association. The null hypothesis for all comparisons in RQ2 were that no association
exists between the independent and dependent variables. Associations were found for two
of the seven covariates, FDA approval year and last host country World Bank income
category. FDA approval year was associated with U.S.-last country drug lag time
category, p < .001, with a moderate-to-large Cramer’s V effect size of .461. Similarly,
last host country World Bank income category was associated with US-Last country drug
lag time category, p < .001, with a moderate-to-large Cramer’s V effect size of .427.
I completed two additional levels of post hoc testing for confirmation of
association between the independent and dependent variables by consolidating categories,
resulting in 4x2 and 2x2 comparisons for FDA approval year and last host country
income level. Consolidation at the 4x2 level confirmed association of for both FDA
approval year, p < .001 and last host country income category, p < .001, with moderate
Cramer’s V effect sizes of .367 and .339, respectively. Further consolidation of each
independent and dependent variable into 2x2 tables reveals that association of FDA
approval year and U.S.-last country drug lag is not significant, p = .801, whereas
consolidation of last host country income category and drug lag into a 2x2 table
maintains an association p < .05 with a small-to-moderate Phi effect size of .20.
Interpretation of the Findings
Both descriptive and inferential analyses of the data collected were enlightening
beyond what is present in the research literature on global availability of new drugs
developed in the relatively recent, new era of globalized clinical trials. When the term
drug-lag was coined by Wardell in a 1973 paper, the observation was the opposite of
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what has been observed in this study, namely, the United States was the country where
approvals of new drugs lagged behind those of the United Kingdom and the EU (Wardell,
1973). Several legislative steps in the 1980s and 1990s, including the FDA modernization
act, the institution of user fees, and legislated, transparent timelines for action dates for
new drug applications have had a positive effect on availability of NMEs in the United
States (U.S. FDA, 2017d; Somerville & Kloda, 2015; Wileman & Mishra, 2010).
These prior evaluations of drug lag in the literature have, however, focused on the
economic and regulatory components of drug-lag versus examining how the magnitude
of drug lag is directly related to the ethical principle of justice for research participants
and host communities. All patients participating in global clinical trials share the
unknown risks of side effects and lack of efficacy inherent in new drug development.
Yet, for those new drugs found to be effective, for research participants and those in their
host countries to remain without access to those approved safe and effective NMEs they
shared the risks of testing while others have access represents an injustice (Hyder, Pratt,
Ali, Kass, & Sewankambo, 2014; Pratt & Loff, 2014). The magnitude of this injustice to
access has not been methodically measured on a time scale from an ethical perspective in
the literature.
The primary research question for this study was descriptive and was to quantify
the magnitude of drug lag, in months, between U.S. approval and the approval in the last
host country of pivotal trials for new drugs first approved in the United States between
2006 and 2015. The results of that U.S.-last country analysis and a comparison to the
U.S.-EU drug lag are presented in Figure 6.

142

Figure 6. U.S.-last country drug lag versus U.S.-EU drug lag in months.

Figure 6 demonstrates the difference in drug lag, by time category, between the
U.S.-Last country and the U.S.-EU, for the 157 products in the sample. The green color
in the pie charts indicates the most expedient approval (approved within 12 months of
U.S.A.) and the gold color indicates the least expedient approval (approved or
unapproved after 60 months) of U.S. approval. The null hypothesis for the primary
research question was that fewer than 66% of drugs would be approved in all host
countries within 12 months of U.S. approval. As indicated in the US-Last Country druglag pie chart, 9.6% of products were approved within 12 months of the US approval,
versus 72% for the EU. Therefore, while the null hypothesis for the primary research
question is accepted for the US-Last Country drug lag, the null hypothesis would have
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been rejected if the drug-lag of primary interest in this study was the U.S.-EU lag.
Though the U.S.-EU lag is understandably shorter than the U.S.-LC and EU-LC lags
based on the size of the EU market, premium pricing, transparency in the application and
approval processes and the concentration of corporate headquarters in the U.S. and EU
for sponsoring companies, the median difference in drug lag between U.S. and EU
approvals to last country approvals remains striking at 63 months and 50 months,
respectively. The Wilcoxon tests support that both the U.S.-Last country and the EU-Last
country drug-lags are significantly greater, (p < .001) than the U.S.-EU lag. These data
indicate that seeking tandem or rapid approval in the EU is a priority for US and EU
sponsors, and that seeking approval in all countries participating in pivotal trials, outside
the U.S. and EU is either a lower priority or a protracted endeavor.
The secondary research question finding of an association of last host country
World Bank income category with drug lag, (p < .001) with a moderate to large effect
size, and post hoc sensitivity testing indicates with confidence that this association is real.
While the sample size is relatively small, of the 157 products tested in 82 countries
between 2006 and 2015, 65 of those countries were World Bank high income, 47 were
upper-middle income, and 45 were lower-middle income. There were no World Bank low
income countries included in the sample. It should be stated however that World Bank
low income countries do participate in US and EU sponsored clinical research, none of
those trials met the inclusion criteria of this study, as either an NME, first approval of the
NME in the United States or deemed by the FDA as a pivotal trial to US approval. Figure
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7 illustrates the World Bank Host Country Income results and associations with drug lag
by category.

Figure 7. World Bank host country income category and drug lag in months.

Figure 7 compares World Bank high income countries in the sample (n=65) to the
combined upper-middle and lower-middle income countries (n=92). Interestingly, in the
combined lower-middle income and upper-middle income countries, 1 of 92 products, or
1.1% were approved within 24 months of the U.S. approval. For the 45 countries in the
lower-middle income group, there were no products approved within 24 months, with the
majority of approvals, 58%, taking 60 months or longer. Finally, for the 65 high income
countries, the distribution of approvals was approximately equal over each of the 4
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categories of drug lag, with 49% of approvals happening within 24 months, indicated by
the green and orange sections of the diagram.
Combining the significant regional drug lag findings from research question 1,
and the strength of the association between World Bank last host country income, a
picture consistent with an economic model for drug approval and marketing appears
(Poitras, 2009). The data support both a pursuit of prioritizing registration in the EU than
in other, non-EU countries when the U.S. is the first approving country. The data also
demonstrate that a prioritization of registration in World Bank high income countries
versus upper-middle and lower-middle income countries, though these samples are
smaller. Other descriptive but not statistically tested data are supportive of this
observation, namely that the mean number of countries participating in pivotal trials in
this sample was 16 and that 72 of the 157 products remain unapproved in at least 1 of the
81 countries included in this sample.
The independent variable year of FDA approval, as one of the 7 tested in research
question 2, originally demonstrated an association with the dependent variable, drug-lag
category, (p < .001) with a moderate to large effect size. I noted that 3 elements of this
association were potentially problematic, however. The first was variability in the
number of approvals per year, from a low of 9 in 2008, to a high of 24 in 2015. I also
noted that the approvals largely increased on an annual basis between 2006 and 2015,
with 57 approvals in years 1-5 and 100 approvals in years 6-10 of the sample period.
Finally, with respect to the dependent variable, drug lag category, I noted that,
considering the cutoff date of April 1, 2019 for all approvals, that for the years 2014 and
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2015, for the majority of products the maximum drug lag category would be the Delayed
category, i.e. between 25 and 60 months. These concerns prompted me to perform
additional, post hoc sensitivity testing which included combining the categories for each
variable. First, I combined the individual years of approval into 2 categories, 2006-2010
and 2011-2015, and left the 4 categories of the dependent variable the same, yielding a
4x2 table for chi square testing. This resulted in the significance of the association
remaining the same (p < .001), but with a reduction in the effect size from the original
moderate to large effect size (Cramer’s V = .461) to a moderate effect size of (Cramer’s
V = .367). As second step of sensitivity testing was conducted by reducing the dependent
variable to 2 categories, with 0-12 months as 1 category, and 13 months or greater as the
other category, resulting in a 2x2 table for chi square testing. The second step results
indicated a non-significant p value (p = .801) for association between FDA approval year
and drug lag category.
None of the other 5 independent covariates tested by chi square analysis as part
of research question 2 were found to have an association with the categories of U.S.-Last
country drug-lag. Given the strength of the association observed between World Bank
last host country income category and drug lag, it was somewhat surprising that neither
orphan indication nor FDA review type, nor sponsor market capitalization had any
association with drug lag category, however given the clear prioritization of EU approval
observed in this study, this assumes an economic model for prioritizing global drug
approvals prevails in this sample.
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It is also noted that there is no easily accessible information on what trials are
considered pivotal versus supportive, and there is significant variability in access to
information about what countries participated in those pivotal trials. Ready, on-line
access to information regarding the approval dates and availability of drugs on a countryby-country basis in English was available in approximately 70% of the countries in this
study, whereas for the remaining 30% a combination of direct sponsor contacts and a free
subscription to a proprietary database, ADIS insight from Springer Publications assisted
in completing the collection of the missing approval dates and data. Several sponsor
practices were noted on clinicaltrials.gov, one of the main sources for participating
country information, which complicated data collection on specific pivotal trials and
participating countries were; failure to include the specific protocol number in the
posting, and a practice of designating one point of contact to distribute information on the
location of participating sites. These practices made it challenging at times to determine if
a trial was pivotal, and/or which specific countries participated in that trial.
Aristotle’s concept of a society’s duty to contribute to the flourishing overall
health is the foundational concept of both the Health Capability paradigm and the RHJ
framework, which is most relevant to the role of medical research in enriching societal
health, particularly in low-and-middle-income countries (Papadimos, 2007; Pratt & Loff,
2014; Ruger, 2010; Taylor, 1956). The fundamental premise of the health capability
paradigm is that societies, be they state or federal governments have an interest and
mandate in both promotion of overall health but also to decrease inequalities, by ensuring
just distribution of benefits throughout the population (Ruger, 2010). In cases where
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states or countries themselves may lack the resources or necessary expertise to provide
for their populations, then this paradigm proposes that more affluent states, countries,
organizations and corporations are ethically bound to contribute goods, services and
know how to address these gaps in health and the capability of becoming as healthy as
the most affluent, healthiest nations (Pratt & Loff, 2014; Ruger, 2010). The health
capacity model also states that a state of health capacity justice can only exist when,
global organizations continuously monitor the status of countries which have health
related shortfalls and actively assist these states to reduce those health and health capacity
shortfalls (Pratt et al., 2012). This concept is directly relevant to the development of a
new drug treatment by international pharmaceutical companies headquartered in affluent
regions. As the state of knowledge and therapeutic armamentarium increases through new
drug development, whether or not the populations with health capacity shortfalls
participated in pivotal clinical trials, if global access is not provided to those therapeutic
advances, an injustice has been created with respect to health capacity, as the ability to
flourish of the under-served population is diminished in comparison to the countries
which have access to the advanced treatment.
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Figure 8. Research for health justice framework.

Specifically, as it pertains to international clinical research, the RHJ framework,
figure 8, builds upon the tenets of the Health Capability paradigm to guide the
conceptualization of clinical trials on a global scale, particularly when trials include Low
and Middle income countries (Pratt & Loff, 2014; Pratt et al., 2012). Conceptualizing
specifically what, or who the research targets are, with knowledge and appreciation of the
state of health and development in the proposed population is an important consideration
from the outset of research design. However, with the globalization of clinical research,
clinical protocol design strives largely for consistency and portability to a variety of
healthcare settings, with the goal of international regulatory approval for the drug being
tested and therefore is often insensitive to local population considerations (Tufts Center
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for the Study of Drug Development, 2009). The second tenet of the RHJ framework,
strengthening of research capacity at the local level is frequently fulfilled by the sponsors
of clinical trials, as it is in their interest to train the clinical investigators and their staff in
the research protocol, to provide any necessary supplies, equipment and instruments
which potentiate objective measurement of clinical data. Finally, the RHJ framework
requires, from the time of research conceptualization, the consideration of post-trial
benefits, and what forms those benefits may take (Pratt & Loff, 2014).
Because globalization in clinical research into lower-and middle-income countries
has happened relatively quickly, many sponsors, investigators and contract research
organizations have viewed each clinical trial on a single transactional basis, versus as a
part of a continuum of health benefits or elements contributing to the overall health
capability of a population. There has also been a failure of sponsoring companies and
contract research organizations to appreciate that the burdens, risks and benefits of the
research are experienced not just by the research participants themselves, but their
communities (Pratt & Loff, 2014; Pratt et al., 2012) International organizations, local
Ministries of Health, clinical investigators, advocates, ethics committee members must all
have the benefits of training and interactions with research sponsors who propose to
introduce a potential new treatment into their communities (NCOB, 2005; UNAIDS,
2012).
Finally, while it is logical to require that sponsors make all drugs available to all
populations which hosted the research, there are situations which may ethically preclude
doing so, and an alternative post-trial benefit is of equal or greater value to the host
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country’s population (Pratt & Loff, 2014). Some examples where post-trial access to the
drug under study is precluded; if the drug has an unpredictable safety and efficacy
profile, calling the benefit to risk into question, a change in access to properly trained
practitioners familiar with the drug’s use, infrastructure elements such as cold-chain
transport and storage, access to necessary monitoring equipment to ensure safe use which
cannot be replaced, and others. In such cases, there may be an alternative treatment or
intervention that the research sponsor can provide increases community health capacity,
without the accompanying risks introduced by the new drug. Regardless, all communities
where research is performed and inequalities exist must be monitored for opportunities to
increase health capacity by more affluent countries, companies and international
organizations (Pratt et al., 2012).
Limitations of the Study
All data in this study were collected from secondary sources, which I neither
designed nor administered, and thus, is an inherent threat to internal validity if the
sources themselves were not constructed or maintained in a high-quality manner. Sources
including the FDA, EMA, dozens of national ministry of health websites and
downloadable formulary spreadsheets, as well as centrally maintained data archives such
as clinicaltrials.gov, the EU clinical trials registry, the World Bank, the New York Stock
Exchange, NASDAQ and the ADIS Insight data aggregation product from Springer
Publications all have differing specifications and procedures for quality control. Errors of
inclusion or omission could be present within each source, which could impact the
internal validity of the data set I derived for the primary and secondary analyses. I also
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hand-entered portions of the data, such as those portions from the FDA websites which
were all available only in PDF format. If there were systematic, entry, or random errors in
any of these secondary sources, then the observations, analyses and inferences relying on
incorrect or discrepant data could be incorrect (Creswell, 2014).
External validity is threatened when there are conclusions reached, or over-broad
generalizations made which extend, inappropriately, beyond a reasonable scope of what
the sample can represent (Creswell, 2014). Limitations to external validity and the
introduction of bias are possible any time inclusion and exclusion criteria designed to
sample a population, including groups of studies included in meta analyses are
implemented (Ahn & Kang, 2018). The inclusion criteria and sampling method and
several of the sources in my study was similar to 3 other studies which considered 1-year,
2-year, and 10-year reviews of FDA NME approvals for different objectives, therefore I
have confidence that the sampling criteria and sampling method are valid and acceptable
(Homedes & Ugalde, 2016; Larochelle et al., 2017; Wileman & Mishra, 2010).
Importantly, this study examines the drug-lag between therapeutic NME products
first approved by the FDA between the years 2006 and 2015, which included pivotal
trials with at least 1 host country outside the United States. 92% of the sponsoring
companies were headquartered in the United States or EU. The sample also represents
54%; or 157 of the 291 FDA NME approvals which occurred during the sampling period,
therefore inclusion and exclusion criteria reduced the eligible sample size by
approximately 46%. This study also does not consider overall FDA annual approvals
during the sampling period which include generic medications and new formulations of
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previously approved products. While the data provide actual approval dates, or a cutoff
date for each product in each country which participated in pivotal trials, there is no
information on corporate prioritization, decision making, or country-by-country
regulatory challenges which may have been faced by sponsoring companies which
impacted the approval date, or lack thereof, recorded for each host country. It should also
not be assumed in all cases when a drug is not yet approved in a host country, that all
research participants have had their treatment discontinued, as continued access to new
products may be available by extension protocols, compassionate use or expanded access.
Results and inferences, therefore, should be interpreted and extrapolated with caution
beyond those contexts.
Recommendations
Awareness of ethical considerations of globalization of clinical research
sponsored by pharmaceutical and biotechnology companies headquartered in high
income countries is present in the peer-reviewed literature and among various
international organization documents relating to human rights (CIOMS, 2016; NCOB,
2005; WMA, 2013). However, quantitative evaluation of the magnitude of drug-lag from
the perspective of the ethical principle of justice is lacking. Because the enterprise of
drug development involves research in human subjects who take risks for potential but
unknown benefits, sponsors of global drug development must include contingency plans
for success and failure which consider the human right to well-being, and the social
justice of access to new treatments for disease. Using U.S.-EU, U.S.-Last country and
EU-Last country drug-lags as surrogates to measure how sponsor companies prioritize
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access to new treatments, the regional differences in prioritization elucidated by this
study can offer insights into improving justice for research participants and overall global
access to new treatments.
To add transparency to the clinical research and development process, sponsoring
companies could adopt a culture of greater public disclosure of their research and
development activities. Details such as listing all countries hosting their clinical trials,
providing protocol numbers and dossiers organized by product and indication on public
registry websites such as clinicaltrials.gov and the EU clinical trials registry could be
updated more urgently and frequently and improved organizationally and for content.
Regulatory agencies could provide searchable versions of their review and approval
documents and organized, product specific meta-data on public websites to facilitate
research on product development. Sponsors themselves and/or individual ministries of
health could host web-interactive drug formularies in English including details on all
approved products, in each country, their date(s) of approval, indications, doses,
availability and retail prices.
To add specificity to this study’s findings, future studies could use a survey
methodology to explore the specific reasons that sponsoring companies do not pursue or
achieve global approval of their products receiving approval in the United States and the
EU. Such a method would depend upon significant disclosures from sponsor companies,
portions of which some may consider to be proprietary information, therefore interjecting
the potential for missing data. Future studies would also depend upon sponsoring
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companies’ buy-in to the validity of drug lag as a surrogate for justice and equality of
access, particularly to prior research participants and their communities.
Implications for Professional Practice and Positive Social Change
Professional Practice
This study illustrates expediency in the time to new drug approval for the
European Union and World Bank high income countries versus other countries which
participated in pivotal clinical trials outside the EU. Whether this difference results from
strategic economic corporate decision making, or complicated regulatory processes in exU.S., ex-EU countries is unknown. The results of this study could benefit pharmaceutical
and biotechnology corporations sponsoring global clinical research to hasten the approval
of their new treatments, by elucidating the need for transparency among all companies
engaging in global clinical trials. Improving transparency of companies, regulatory
agencies and ministries of health will allow identification of countries where injustices in
new treatment access are greatest and allow focus on solutions to diminish those
inequalities.
Methodologically, encouraging a culture of social responsibility and transparency
among those sponsoring global clinical research as can be measured by metrics such as
drug-lag sets a standard for new companies entering the environment and allows a more
ready identification of the most appropriate population(s) in which to conduct clinical
research. Identifying minimizing the gaps in global access to new treatments as one of the
key company values and an important performance indicator can generate a culture of
shared responsibility of improvement in global health. If more sponsors responsibly
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invest in the healthcare infrastructure of emerging countries as part of pre-trial capability
building, and/or as part of post-trial responsibility, the health capability of societies is
improved. Finally, an increase in valuation of the social responsibility component of the
corporate bottom line in the pharmaceutical and biotechnology industries, if accepted by
company executives, industry trade organizations and shareholders, must occur for truly
positive professional changes to maximized. Such changes involve modification of the
current thinking of the pharmaceutical and biotechnology industries that new treatments
are to be regarded as more similar to other consumer products than they are different. If
the differences in corporate responsibility between developers of new therapeutic
treatments for diseases and other consumer products can be ubiquitously acknowledged,
then a new standard for transparency, access and justice may have a greater probability of
adoption on a global basis.
Positive Social Change
My study has identified an opportunity in which sponsoring companies can
improve the time to providing global access to their products, particularly to each country
which hosted the clinical trials deemed as pivotal to the product’s FDA approval. By
elucidating what appears to be a corporate prioritization of approval in the largest, highest
income and most premium priced markets, an opportunity exists for companies to take a
more holistic approach and to ensure accessibility of their products not just to the direct
research participants themselves, but to the entire communities an societies which
supported the clinical trials responsible for the approval of new and valuable advances in
the treatment of disease. Corporate leaders, ministries of health, members of ethics
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committees, legislators, clinical investigators, community leaders, trade organizations and
corporate shareholders are all stakeholders in the positive social changes which could
drive a re-direction in the company priorities for those involved in the research,
development, approval and access to new treatments for disease.
Conclusion
This study was built upon three main premises. The first is that new molecular
entities approved by the U.S. FDA represent therapeutic advances in the treatment of
disease. The second is that drug-lag is a reasonable quantitative measurement and a
surrogate for the ethical principle of justice, as it relates to the availability of new
treatments to the populations of research subjects and their communities which took the
risks to test these therapeutic advances in clinical trials. The third premise was pragmatic,
and assumes that availability of these new treatments within 12 months of FDA approval
is a reasonable and ethical time-frame, given administrative requirements for registration
of new drugs in different countries.
The results of this study demonstrate that, for drugs in this sample first approved
by the FDA between 2006-2015, there is a significant difference between the lag time to
European Union approval, and approval in the last country which hosted pivotal clinical
trials for each product. The majority of these new treatments were approved by the EU
within 12 months of the FDA’s approval, whereas in the last host country, the majority
were not approved within 5 years of the FDA’s approval. A significant association was
also found between the World Bank income level of the host country and the magnitude
of the drug-lag, showing that high income countries are more likely to have approval of
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new drugs sooner than upper-middle and lower-middle income countries. Finally, nearly
half of the products in this sample which were FDA approved between 2006 and 2015
remain unapproved in at least 1 host country, as of April 1, 2019.
To date, host country drug-lag has not been included as a surrogate for justice in
the availability of treatment advances for disease. Given the increase in globalization of
clinical research in the past 2 decades and predominance of U.S. and EU sponsoring
companies developing new treatments for disease, drug-lag is a simple measurement of
social justice and corporate social responsibility which could easily benchmark
companies ethical performance to each other. Such objective benchmarking may
ultimately increase global access to new treatments and diminish inequities in social
justice relating to access to new treatments for disease, simultaneously.
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